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Metastasis-mediated mortality remains a major challenge in the management of colorectal cancer 
(CRC). One of the key findings in understanding molecular pathogenesis of colorectal cancer 
metastasis is the identification of the new gene MACC1. MACC1 has been reported as a 
prognostic biomarker for tumor progression and metastasis-free survival in CRC along with other 
solid tumors. The five-year survival rate has been shown to be 80% for subjects with low MACC1 
mRNA expression and only 15% for subjects with high MACC1 expression. It also induces cell 
motility and proliferation in cell culture and metastasis in mouse models. Consequently, targeting 
MACC1 to intervene in tumor progression and metastasis formation holds a promising approach 
to treat CRC patients.  
We designed a strategy to inhibit MACC1 via targeting its transcription. Therefore, we started with 
the identification of the MACC1 gene promoter by creating various promoter-luciferase constructs 
and studied its transcriptional regulation machinery. Using site directed mutagenesis, chromatin 
immunoprecipitation and electrophoretic mobility shift assays, we established that transcription 
factors such as Ap-1, Sp1, C/EBPs and GIPC1 bind to the MACC1 promoter and govern the 
transcription of the MACC1 gene. RNAi technology followed by analysis of a panel of colorectal 
carcinomas of various stages established the role of these transcription factors in MACC1-
induced cell motility in vitro and in vivo. 
Further, by employing high throughput screening targeting the MACC1 promoter, we identified the 
very first small molecule MACC1 inhibitors, Rottlerin and Lovastatin. Rottlerin and Lovastatin 
were shown to specifically act on the endogenous MACC1 promoter leading to reduced MACC1 
expression in a time- and concentration-dependent manner. Further in vitro functional assays 
demonstrated the impact of the small molecule inhibitors on retarding cell proliferation and 
motility. Both the small molecule inhibitors restricted Sp1 levels and interfered with the binding of 
c-Jun to the MACC1 promoter, thereby inhibiting MACC1 transcription and MACC1-induced 
proliferation and migration. The study further described the effect of Rottlerin on a CRC-
xenografted mouse model. Daily treatment of xenografted mice with Rottlerin resulted in the 
inhibition of MACC1 expression in the primary tumor accompanied with the restricted tumor 
growth. 
To summarize, this is the first study unraveling the MACC1 promoter and its transcriptional 
regulation. This knowledge was then implicated to identify small molecules, Rottlerin and 
Lovastatin as newly identified MACC1 inhibitors. In clinical settings, inhibition of MACC1 
expression using these inhibitors might provide immense potential for the treatment of CRC 









Die Metastasen-bedingte Mortalität bleibt weiterhin eine große Herausforderung in der 
Behandlung des kolorektalen Karzinoms (KRK). Einen wesentlichen Fortschritt zum 
Verständnis der molekularen Pathogenese des Metastasierungsprozesses im KRK trug die 
Identifizierung des neuen Gens MACC1 bei. MACC1 wurde als prognostischer Biomarker für 
die Tumorprogression und das Metastasen-freie Überleben im KRK sowie in anderen soliden 
Tumoren beschrieben. Die 5-Jahres-Überlebensrate betrug hierbei 80% für Patienten mit 
niedriger MACC1 mRNA Expression im Vergleich zu nur 15% für Patienten mit hoher 
MACC1 Expression. Das Gen induziert Zellmotilität und Proliferation in Zellkultur sowie die 
Metastasierung im Mausmodell. Letztendlich stellt MACC1 ein vielversprechendes Ziel für 
die Intervention bei Tumorprogression und –metastasierung und damit für die Behandlung 
von KRK-Patienten dar. 
Unser Versuchsvorhaben war es, MACC1 über seine transkriptionelle Expression zu 
inhibieren. Hierfür identifizierten wir zunächst die Genpromoter-Region von MACC1 durch 
das Erstellen verschiedener Promoter-Luciferase Konstrukte und untersuchten MACC1s 
transkriptionelles Regulationsnetzwerk. Durch ortsgerichtete Mutagenese, Chromatin 
Immunopräzipitation und Electrophoretic Mobility Shift Assay ermittelten wir, dass 
Transkriptionsfaktoren wie Ap-1, Sp1, C/EBPs und GIPC1 an den MACC1-Promoter binden 
und die Transkription des MACC1-Gens kontrollieren. Durch Verwendung von RNAi-
Technologie und der Analyse einer KRK-Patientenkohorte mit verschiedenen Tumorstadien 
etablierten wir die Rolle dieser Transkriptionsfaktoren in der MACC1-induzierten Zellmotilität 
in vitro und in vivo. 
Darüberhinaus konnten wir durch Hochdurchsatz-Screening die bisher ersten Kleinmolekül-
Inhibitoren gegen MACC1 identifizieren: Rottlerin und Lovastatin. Wir zeigten, dass Rottlerin 
und Lovastatin spezifisch auf den endogenen MACC1-Promoter wirkten, was eine zeit- und 
konzentrationsabhängige Reduktion der MACC1-Expression zur Folge hatte. Weitere 
funktionelle Versuche in vitro demonstrierten, dass die Kleinmolekül-Inhibitoren 
ausschlaggebend für die Verminderung von Zellproliferation und -motilität waren. Beide 
Inhibitoren begrenzten das Expressionsniveau von Sp1 und interferierten mit der Bindung 
von c-Jun mit dem MACC1-Promoter, was in einer Inhibition der MACC1-Transkription sowie 
der MACC1-induzierten Proliferation und Migration resultierte. Ferner führte die tägliche 
Behandlung von Xenograft-Mausmodellen mit Rottlerin zu einer Inhibition der MACC1-






Zusammenfassend lässt sich festhalten, dass in der vorliegenden Arbeit zum ersten Mal der 
MACC1-Promoter und seine transkriptionelle Regulation beleuchtet wurden. Die neuen 
Erkenntnisse wurden außerdem zur Identifizierung der ersten Kleinmolekül-Inhibitoren gegen 
MACC1 genutzt. Zur Behandlung von KRK-Patienten mit einem hohen Risiko für MACC1-
induzierte Metastasierung und damit kürzerer Überlebenszeit, könnten diese Inhibitoren 












































1.1 Colorectal cancer: Incidence and epidemiology 
Colorectal cancer (CRC) is the third most common cancer in men and second in women, 
worldwide [1]. CRC dominates over all gastrointestinal cancers and continues to be in the 
spotlight owing to its high prevalence and long progression time of the premalignant lesion 
along with expensive and invasive screening procedures. The highest rate of incidence 
among both genders are reported in east European countries (Czech Republic and 
Slovakia), Japan (Miyagi), New Zealand, Australia, Germany, and among African Americans, 
whereas the lowest rates are found in Africa, Central and South America, and South Central 
Asia (India and Pakistan) [1]. Five-year survival rates for CRC in developing countries range 
from 28% to 42% [2, 3], compared to more than 60% in the United States, Japan, and 
Switzerland [4, 5]. Within Germany, CRC is the second most common cancer and third most 
common cause of cancer associated mortality in female whereas in male, it is the third most 
common cancer and second most common cause of cancer associated mortality [6]. The 
overall age adjusted survival rate for CRC patients within Germany over the period 2002-
2006, has significantly increased from 60.6% to 65%. This increase is specific for patients 
with localized cancer as no improvement in overall survival has been achieved for patients 
with metastatic disease [7]. A multitude of risk factors have been linked to CRC, majority 
being sporadic. Risk factors include increasing age, diet, lifestyle (eg. high consumption of 
red meat, fat-rich diet, lack of exercise and obesity, inadequate fiber intake, excessive 
smoking and alcohol), environmental exposures, and chronic inflammatory syndromes 
affecting the gastrointestinal tract (Ulcerative colitis and Crohn‟s disease) [8]. Inherited 
conditions such as familial adenomatous polyposis (FAP) and hereditary nonpolyposis 
colorectal cancer (HNPCC), also called Lynch syndrome, account for approximately 5 to 10% 
of all CRC cases [9]. HNPCC is associated with mutations in genes involved in the DNA 
repair pathway, namely the MLH1  (MutL homolog 1, colon cancer, nonpolyposis type 2) 
and MSH2 (MutS protein homolog 2) genes [10] and FAP is caused by mutations in the 
tumor suppressor gene APC [11]. They will be discussed in detail in the later sections. 
1.2 Tumorogenesis and cancer progression 
Tumorogenesis of CRC is a complex process involving both environmental and genetic 
factors [12]. This multistep process is an outcome of the interactions between environmental 
influences, germ-line factors dictating individual cancer susceptibility and accumulated 





understand the molecular origin of CRC. Researchers, worldwide are still trying to pinpoint 
the exact mechanism that initiate tumor development, its progression into an invasive and 
metastatic phenotype and its responsiveness or resistance to therapies. Colorectal 
carcinogenesis involves two major pathways. One of them is called the “canonical” 
(adenoma-carcinoma sequence) or “suppressor” or “traditional” pathway and involves 
chromosomal instability (CIN) leading to tumor progression [14]. This traditional pathway is 
characterized by mutation in the APC gene or allelic losses on chromosome 5q (APC gene), 
mutation in KRAS, loss of 18q (DCC/SMAD4) and 17p (p53).  
The second pathway of colorectal carcinogenesis involves microsatellite instability (MSI), and 
is called as the “mutator” pathway. It is characterized by defects in the mismatch repair 
system (MMR genes) thereby interruption of the DNA damage repair system (Fig. 1.1) This 
pathway accounts for approximately 15%-20% of sporadic CRCs [15]. These two pathways 
present different molecular and clinical behavior along with distinct histopathological features 
and are described in the next section. 
1.3 Canonical pathway 
This pathway is responsible for the development of a majority of colorectal carcinomas and is 
based on the Fearon and Vogelstein model of colorectal carcinogenesis. Fearon and 
Vogelstein proposed specific genetic events with evolving tissue morphology (Figure 1.1) 
leading to CRC progression. Alterations in tumor suppressor genes (APC, p53, DCC) and 
oncogenes (KRAS, CTNNB1 encoding β-catenin) with high frequency of allelic imbalance, 
chromosomal amplification and translocations are characteristics of this pathway. These will 
be discussed in details along with the signaling pathways they affect in the following 
sections. 
1.3.1 APC, β-Catenin and Wnt signaling 
The adenomatous polyposis coli (APC, 5q21) gene is mutated in approximately 60% of 
cancers arising from the colon and in 82% of cancers in the rectum [16]. It is a major unit of a 






Figure 1.1: Two major pathways for CRC. CRC progression follows a series of genetic and 
epigenetic changes giving rise to adenoma-carcinoma sequence. The majority of CRCs show 
chromosomal instability and are characterized by gain or loss of chromosome 5q (APC), 18q (DCC, 
SMAD4) and 17p (p53) as shown in red, whereas a subgroup of CRCs show defects (methylation of 
promoter or mutations) in DNA mismatch repair genes (in blue) leading to accumulation of mutations 
in microsatellite sequences. Modified after Moran et al. [17, 18] 
 
This multi-protein complex binds to β-catenin and causes its phosphorylation, subsequent 
ubiquitination, and thus ultimately leading to its destruction in the proteasome. APC 
mutations interfere with APC-β-catenin binding, impairing the degradation of cytoplasmic β-
catenin, which is then available to translocate to the nucleus resulting in constitutively active 
Wnt-signaling pathway. However, in tumors lacking APC mutations, mutations at codon 31, 
33, 37 and 45 of exon 3 of the CTNNB1 gene render the protein resistant to APC-
degradation and act as an alternate way of activating the Wnt signaling [19]. The frequency 
of APC or β-catenin mutations in early adenomas is as high as 80 to 85% suggesting that 
these genetic alterations initiate tumorogenesis in the intestine in a process characterized by 
the formation of dysplastic crypts and early adenomas [20, 21]. 
In addition, APC also plays a role in regulation of mitosis by ensuring correct chromosomal 
alignment and subsequent segregation during metaphase [22]. Therefore, loss of APC 
results in chromosomal abnormalities during metaphase contributing to CIN [23]. Hence, 
mutations in APC and the Wnt-pathway are a frequent mechanism for progression of early 
lesions to more advanced stages of CRCs. However other genetic alterations may also serve 





1.3.2 KRAS and MAPK signaling 
The KRAS proto-oncogene is a GTP-binding protein located at chromosome 12p12.1. It 
regulates several effector pathways involved in cell proliferation, survival and metastasis [24]. 
GTP bound KRAS (active Ras protein) phosphorylates MAP3K (Raf), which further activates 
MAP2K (MEK-1/2), subsequently phosphorylating MAPK (ERK-1/2), thus activating the 
MAPK signaling cascade. Although MAPK cascade is also activated by other non-KRAS-
mediated growth factor pathways, signaling in cancer is frequently deregulated through 
activating mutations in KRAS or BRAF [25]. 
Oncogenic KRAS mutations are detected in approximately 40% CRCs with most frequent 
mutations in codon 12 and codon 13 [26]. These mutations are more frequent in advanced 
adenomas despite being frequent up to 63% in sporadic dysplastic aberrant crypt foci (ACF). 
Thus, KRAS is not sufficient to drive carcinogenesis but certainly confers a growth advantage 
for the progression of CRC [27]. KRAS mutations are present in both adenomas and 
hyperplastic polyps suggesting that KRAS mutations are not the predominant precursors of 
either type of colorectal tumor in contrast to APC mutation which is closely associated with 
the initiation of adenomas [21]. 
1.3.3 SMADs, DCC and TGF-β signaling 
DCC (deleted in colorectal cancer), SMAD2 and SMAD4 genes are all located at 
chromosome 18q21.1. Approximately 60% of CRCs show allelic loss at this site [28]. Germ 
line mutations in SMAD4 can cause juvenile polyposis syndrome, associated with 
gastrointestinal polyps and cancer [29]. In sporadic CRCs, so far it was known that SMAD4 
mutations are more influential in colorectal carcinogenesis and are often reported in 
advanced stages of CRCs [30, 31]. However, a recent study demonstrates first substantial 
contribution of SMAD2 and SMAD3 in sporadic CRCs occurring in 3.4% and 4.3% of primary 
cancers, respectively [32]. SMADs are TGF-β superfamily members and  have been shown 
to control proliferation, differentiation, migration and apoptosis of many different cell types 
[33]. TGF-β is an important inhibitor of growth [34]. In colorectal carcinogenesis, an escape 
from TGF-β induced-inhibition of proliferation has been observed leading to uncontrolled 
growth [35]. SMADs play a central role in TGF-β signaling. They are divided into three 
groups based on their role in signal transduction. First group comprises of receptor activated 
SMADs wherein, SMAD2 and SMAD3 are phosphorylated by different type I serine threonine 
receptors of the TGF family. SMAD1, SMAD5 and SMAD8 are phosphorylated by receptors 
for bone morphogenetic proteins (BMPs). Second group consists of common mediator 





complexes to the nucleus for regulating target gene expression. The third SMADs category is 
inhibiting SMADs, SMAD6 and SMAD7. These inhibitor SMADs either block phosphorylation 
of receptor-activating SMADs or compete with complex formation with SMAD4 [36]. Activated 
SMADs regulate diverse biological effects by cooperating with transcription factors resulting 
in cell-state specific modulation of transcription. 
DCC encodes a transmembrane receptor which binds to its ligand, netrin-1. Wild-type DCC 
in the absence of netrin-1, promotes apoptosis by activating caspase-3 as well as induces 
G2/M cell-cycle arrest in some cell lines [37]. Also, in the presence of netrin-1, DCC activates 
Rac-1 which contributes towards actin organization and cell motility [38]. 
1.3.4 TP53 
Tumor suppressor gene TP53 encoding p53 is located on chromosome 17p13.1. The 
functional p53 gene facilitates DNA repair by inducing G1 cell-cycle arrest and by elevating 
the expression of cell-cycle retarding genes thereby providing sufficient time for DNA repair 
during environmental or oncogenic stress [39, 40]. In case of extreme genetic stress, it 
induces apoptosis which is a major p53 associated cellular process [41]. Mutation or loss of 
heterozygosity (LOH) in this gene is associated with various human cancers [42]. 
Particularly, in CRC‟s, as described by Fearon and Vogelstein adenoma-carcinoma 
sequence, p53 associated abnormalities are late events. It marks the transition from pre-
invasive adenoma to invasive cancer disease. The frequency of p53 alterations (4%-26% of 
adenomas, 50% of adenomas with invasive foci, and in 50%-75% of CRCs) increases with 
the progression of lesion within the pathway [14, 43]. Thus to conclude, p53 gene usually 
remains unaffected throughout the progression from normal mucosa to adenoma 
development. During a later event of tumorogenesis, however, expression of wild-type p53 
may become rate limiting for cell growth. At this point, p53 point mutations and allelic 
deletions might occur very rapidly and are likely to contribute to progression to carcinoma 
stage [44]. 
1.4 Microsatellite instablilty pathway 
The majority of CRCs follow traditional pathway involving chromosome instability 
characterized by loss or gain of chromosome arms, translocations, or gene amplifications. 
But nearly 15%-20% of sporadic CRCs display „„mutator‟‟ phenotype or Microsatellite 
instablilty pathway (MSI) pathway [45].  In contrast to CIN tumors, they are characterized by 
inactivation or mutation in DNA mismatch repair (MMR) genes. The MMR system consists of 





associate with their partners MutS and a MutL, to form functional heterodimers [46]. Defects 
in the MMR system leads to accumulation of errors in DNA, mainly frame shift mutations, 
within short repeat sequences referred to as Microsatellites (MSI) [47]. Mutations or 
epigenetic changes in hMLH (often silencing caused by methylation) and hMSH2 are key 
components of MMR system and thus the most common cause of MSI-H in sporadic CRC 
and in HNPCC, Hereditary Non Polyposis Colorectal Cancer [15, 46]. One of the 
consequences of germ line MMR mutation is Lynch syndrome, responsible for one fifth of all 
MSI CRCs. The more common non-familial MSI CRC is due to epigenetic inactivation of 
MLH1 along with the hypermethylation of the surrounding promoters of multiple genes, i.e. 
CpG island methylator phenotype (CIMP+) [48, 49]. These sporadic tumors also show co-
occurrence of BRAFV600E mutations that serve to distinguish them from Lynch syndrome 
[50]. The most intriguing difference between CIN and MSI tumors is that the former shows 
one of the hallmark of cancer i.e. aneuploidy whereas MSI-H cancers are usually not 
aneuploidy [51]. Instead in MSI tumors, mutations described in microsatellite sequences are 
present in genes such as TGFβRII, BAX, TCF-4, WISP3, IGF2R [52-56]. Additionally MSI-H 
tumors have distinct clinical and histopathological features such as proximal colon 
predominance, poor differentiation and/or mucinous histology and low frequency of distant 
metastases. The prevalence of MSI is more common among stage II compared with lymph 
node–positive or stage III CRC. MSI is relatively uncommon among stage IV or metastatic 
CRC (4%) [57]. Thus, it is important to identify the right carcinogenic pathway in patients. 
Therefore, MSI testing should be incorporated on several different sporadic polyps, including 
hyperplastic polyps, tubular adenomas, serrated adenomas and mixed polyps to investigate 
whether the adenoma is the precursor lesion in the mutator or MSI pathway, in order to 
design effective treatment strategies. 
1.5 Epithelial-Mesenchymal transition and CRC metastasis 
90% and 75% of patients in stage I and stage II respectively of their disease are cured 
effectively via surgical resections. However, only 15% of the patients with advanced CRC 
survive for more than 5 years. One of the hallmarks of malignant transformation is the ability 
of tumor cells to invade and metastasize [58]. This metastatic dissemination of primary 
tumors to localized or distant organs bears life- threatening consequences. Approximately 
90% of all cancer deaths arise from metastatic growths, leading to compromised treatments 
and a worse disease outcome [59]. Epithelial-Mesenchymal transition (EMT) is the switch 





EMT is a reversible process in which epithelial cells lose their cell-cell adhesion systems, 
their polarity and gain mesenchymal properties with increased migratory capabilities (Fig. 
1.2). Cancer cells via EMT pathway detach from  the neoplasm,  enter into subsequent steps 
of the invasion-metastasis cascade, migrate, enter into blood or lymphatic vessels and 
disseminate into various organs to cause distant metastases [60]. 
 
Figure 1.2: The epithelial-mesenchymal transition in cancer invasion and metastasis. EMT is a 
morphogenetic process in which epithelial cells lose their properties and acquire mesenchymal 
characteristics during embryogenesis and cancer progression. Various mesenchymal cells can be 
derived from primary epithelial cells. Modified after Kalluri et al. and Gout et al. [61, 62] 
 
The nature and type of signaling mediators that contribute to EMT of cancer cells remain 
unknown. One of the hypothesis states that the tumor associated stromal factors like 
Hepatocyte growth factor (HGF), Epidermal growth factor (EGF), Platelet- derived growth 
factor (PDGF), and TGF-β induce EMT and activate EMT-inducing transcription factors, 
notably Snail, Slug, zinc finger E-box binding homeobox 1 (ZEB1), Twist, Goosecoid, and 
FOXC2 [61]. However, a series of signaling pathways involving Extracellular signal-regulated 
kinases (ERK), Mitogen-activated protein kinases (MAPK), Phosphatidylinositol-3-kinase 
(PI3K) , Akt, SMADs, RhoB, β-catenin, lymphoid enhancer binding factor (LEF), RAS, and C-
FOS as well as cell surface proteins such as β4 integrins, α5β1 integrin, and αVβ6 integrin 
also govern EMT [63]. One of the well-established and major events of EMT is the loss of 
functional E-cadherin involved in cell-cell adhesion [64]. The extracellular domain of trans-
membrane E-cadherin interacts with the E-cadherin expressed on adjacent cells, and the 
intracellular domain binds to β-catenin. This β-catenin along with other proteins binds to the 
cytoskeleton. All these together maintain cell–cell adhesion, cell shape, polarity, and cell 
migration [65]. 
Particularly in CRC‟s, loss of functional E-cadherin is linked with peripheral accumulation of 





invasion-inducing T-lymphoma invasion and metastasis 1) and an elevated RhoC expression 
and up-regulation of Snail [66-69]. In addition EMT is associated with a series of molecular 
alterations which include a decrease in expression of epithelial markers and gain in 
expression of mesenchymal markers (Fig. 1.3) [62]. It is also proposed that EMT imparts the 
cancer cells not just migratory abilities but also self-renewal capability by inducing stem cell 
state [70]. Consistent to this, Snail induced EMT also confers a stem cell like behavior as 
shown by the overexpression of stem cell markers like CD133 and CD44 in CRCs [69].  
Finally, the disseminated cells after reaching a particular distant site shed their mesenchymal 
characteristics by the process of mesenchymal-epithelial transition (MET) for secondary 
tumor formation and proliferate again for building up metastases. Thus EMT is the central 
mechanism for progression of carcinomas into the metastatic stage (Fig.1.3). 
 
 
Figure 1.3: Scheme for EMT/MET leading to CRC metastasis. Cells at the primary tumor site 
invade extra cellular matrix (ECM) and undergo EMT-like program to acquire mesenchymal 
phenotype. These transformed cells then intravasate into lymph nodes and blood stream and then 
extravasate into foreign microenvironment (liver in this case). There, they may either stay in an 
EMT/MET equilibrium thereby generating cancer stem cell-like populations or they reestablish primary 
tumor phenotype via MET-like program at distant organs. Modified after Samatov et al. and 
Ramakrishna et al. [71, 72] 
1.6 Current therapeutic scenario for CRCs 
The traditional treatment regimen for CRC is based on the identification of the stage of the 
disease and then performing surgery followed by adjuvant therapy. Surgery (Colectomy) 





early stage CRC‟s that have not spread outside the colon wall (stage 0-1). Patients with 
early, localized stage of CRC have a five-year survival rate of around 90% [73]. 
Unfortunately, like other cancers, CRC manifests itself only when the disease begins to 
progress and is thus diagnosed at later stages. For stage II patients, when cancers have 
grown through the inner wall of the colon and have extended to the nearby tissue, surgery is 
usually followed by adjuvant chemotherapy with 5-Fluorouracil (5-FU) and Leucovorin (alone) 
or Capecitabine. 5-FU is a pyrimidine analogue which gets incorporated into DNA and RNA 
inducing cell cycle arrest and apoptosis. Capecitabine is a pro-drug which gets converted 
into 5-FU inside the tissues whereas Leucovorin enhances the effect of 5-FU by inhibiting 
thymidylate synthetase. In stage III CRC patients, the cancer spreads to the lymph nodes 
and adjuvant chemotherapy in combination with surgery or radiation is the usual treatment. 
So far, there are 9 FDA approved anti-CRC chemotherapeutic drugs. However, 5 of the 10 
anti-CRC drugs are basic cytotoxic chemotherapeutics that inhibit DNA synthesis and thus 
attack cancer cells at a very fundamental level, leaving behind strong side effects on normal 
cells in those patients (Table 1.1). 
 
Table 1.1: Anti-CRC drugs approved by food and drug administration (FDA, USA) 
 
In more advanced cases, when CRC has spread to distant organs in the form of metastasis, 
stage IV, the five-year survival dramatically drops to 12% emphasizing the need to design 
therapies which inhibit metastasis [73]. Combination treatment regimes which include 
chemotherapy/radiotherapy with targeted molecules (Bevacizumab, Aflibercept, Cetuximab, 
Panitumumab, Regorafenib) are routinely followed in such cases. Bevacizumab or 
Aflibercept directed against the vascular endothelial growth factor VEGF prevents the growth 
of new blood vessels to the tumor. Cetuximab or Panitumumab directed against the EGF 
Generic Type Target 
Capecitabine Small molecule DNA synthesis 
Fluorouracil Small molecule DNA synthesis 
Irinotecan Small molecule DNA synthesis 
Leucovorin Small molecule DNA synthesis 
Oxaliplatin Small molecule DNA synthesis 
Regorafenib Small molecule RTK 
Aflibercept Recombinant protein VEGF 
Bevacizumab mAb VEGF 
Cetuximab mAb EGFR 
Panitumumab mAb EGFR 





receptor is used to block mitogenic factors that promote cancer growth and Regorafenib 
targeting angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK), are used to 
treat metastatic CRCs (Table 1.1). However, CRC remains a lethal disease since global 
mortality burden from CRC primarily caused due to metastasis is still very high. Majority of 
the patients do not fully benefit from these treatments. Moreover, the current treatment 
options do not work for every patient because cancers are highly multifactorial and 
heterogeneous in nature. Notably, current chemotherapeutics generically target the growth of 
cancer cells and do not target the various phases of metastasis or cancer stem cells either, 
as they may reside in protective niches within their metastatic sites. Therefore, identification 
of new generation chemotherapeutics as well as better prognostic and predictive markers for 
determining the relevant therapy remains indispensable. 
1.7 Prognostic and predictive markers of CRC 
Prognostic markers are those that define the clinical outcome of a patient in the absence of 
treatment thereby providing the natural history of the disease. Such prognostic markers are 
helpful for identifying patients with cancer who are at high risk of metastatic relapse 
regardless of the treatment. Validation of prognostic factors is relatively straight forward from 
the statistical point of view. A control group from a randomized clinical trial is an ideal setting 
for evaluating the prognostic significance of a biomarker [74]. Predictive markers, on the 
other hand, are those that define the clinical outcome of the patient in response to a 
particular treatment. Thus, predictive biomarker helps in identifying subpopulations of patient 
who are most likely to respond to a given therapy.  Such marker forms basis for personalized 
or tailor made therapy. Predictive biomarker validation requires more extensive data for 
validation, specifically large randomized clinical trials and meta-analysis [75]. One of the very 
effective validation designs is an „interaction‟ design wherein, patients are classified 
according to biomarker level and then randomized to one of two treatments [76]. Moreover, 
predictive markers might also be used as target for therapy. CRC unfortunately is lagging 
behind other cancers in terms of clinically established prognostic marker but the growing 
knowledge and well-designed trials in the recent years promise to fulfill this existing gap. A 
brief summary of promising prognostic and predictive markers in CRC for clinical application 
is described as follows. 
1.7.1 KRAS 
KRAS mutations, mostly in codon 12, 13 and to a lesser extent in codon 61 are mostly 





subsequent activation of MAPK signaling pathway, occurring in about 40% of CRCs [26]. The 
relevance of KRAS as an independent prognostic marker is highly conflicting. According to 
the Kirsten Ras in colorectal cancer collaborative group study (RASCAL) with retrospective 
data analysis from 3439 patients, only glycine to valine substitution at codon 12 (identified in 
8.6% of the cases) was associated with poor prognosis. This particular mutation was found 
to have stronger impact on FFS (failure free survival) and OS (overall survival) in Duke‟s C 
patients [77]. More recently, however, KRAS mutation status has emerged as a predictive 
marker for Anti-EGFR based therapy system. 99% of the patients with mutated KRAS do not 
respond to EGFR inhibition indicating high negative prediction value of KRAS [78]. However 
the response rate for KRAS wild type patients to EGFR inhibition is only approximately 20%, 
suggesting the scope to understand the molecular mechanism corresponding to EGFR 
inhibition resistance in wild type KRAS patients [79]. 
1.7.2 BRAF 
BRAF is a downstream molecule of KRAS in the RAS/RAF/MEK/ERK pathway. Although 
more than 40 somatic mutations in the BRAF kinase domain have been described, the key 
mutation in CRC is the classic GTG  GAG substitution at the position 1799 of exon 15 
(V600E) [80]. Mutations in BRAF and KRAS are mutually exclusive in colon cancer and 
BRAF mutations are most common in CIMP+ and MSI-H genotype [81, 82]. A study from 106 
stage II patients and 258 stage III patients, BRAF mutation was associated with worse OS in 
a multivariate analysis [83]. Another study with 1564 patients with completely resected stage 
II and stage III colon cancer, demonstrated that BRAF V600E predicts poor prognosis in 
microsatellite stable CRC‟s [84] . In the same study, the group reported BRAF V600E 
mutation to be prognostic for OS, especially for MSI-low and MSS patients but not prognostic 
for relapse free survival (RFS).  In contrast, BRAF V600E mutation in MSI-H tumors was 
found to have no impact on OS [85]. BRAF V600E mutation thus partially predicts resistance 
to EGFR inhibitors in patients with wild type KRAS. However, interestingly, a big cohort of 
patients (41%) with wild type KRAS and BRAF did not respond to anti-EGFR based 
treatments, emphasizing the need for further elucidation of biomarkers in this pathway [86]. 
1.7.3 Genomic and epigenomic instability (CIN and MSI) 
The alternate pathway for colorectal carcinogenesis is either by more common CIN (or 
aneuploidy), or through MSI (microsatellite instability). CIN is defined as the presence of 
multiple structural or numerical changes in chromosomes of tumor cells whereas MSI is 
defined as tumors with instability in at least two of the five microsatellite markers [87] as 





of large meta-analyses demonstrating that patients with CIN+ disease have a poorer 
prognosis and patients with MSI+ CRC have a better prognosis then CIN- and MSI- CRCs 
respectively [88-90].  
In addition to being a prognostic marker, several studies have emphasized the predictive 
value of MSI status determining the response to 5-flourouracil (5-FU)-based chemotherapy 
[91, 92]. There have been reports of negative prediction value of MSI+ CRC to adjuvant 5-FU 
therapy [91]. On the contrary, other retrospective study suggest that 5-FU treatment is 
effective in stage IV MSI+CRC patients [93]. In addition, there have been reports suggesting 
that MSI+ CRCs are more sensitive to Irinotecan (inhibits unwinding of DNA by inhibition of 
topoisomerase 1) based therapy [92, 94].  
Additionally, Paclitaxel (a well-established mitotic inhibitor from taxane family used as a 
chemotherapeutic drug for breast, lung and ovarian cancer) sensitivity is based on 
chromosomal segregation in diploid cells, therefore CIN could also be a negative predictive 
marker for response to taxanes [95, 96] . Such studies are currently underway. Nevertheless 
it is reasonable to look for CIN and MSI status to stratify patients and meanwhile more 
retrospective investigation needs to be done to validate the predictive value of MSI and CIN. 
1.7.4 PIK3CA 
Phosphatidylinositide-3-kinases (PI3K) are kinases involved in various biological process 
including proliferation, differentiation, survival, motility which in turn are involved in cancer 
[97]. 10% to 20% of colorectal tumors have been reported to have PIK3CA mutations [98]. 
Activation of these pathways by mutations in KRAS, BRAF, and/or PIK3CA is an established 
mechanism that drives colorectal carcinogenesis [99]. The majority of 
activating PIK3CA mutations map to 3 sites: exon 9, codons 542 and 545 in the helical 
domain, and exon 20, codon 1,047 in the kinase domain, with exon 9 and exon 20 mutation 
being the hotspot targets. Within exon 9 and 20, the most common transversion are 
c.1624G>A (E542K) and c.1633G>A (E545K) in exon 9 and c.3140A>G (H1047R) in exon 
20 [100]. 
The prognostic value of PIK3CA mutations in CRC for patient survival remains unclear. 
Various studies have established the role of PIK3CA as a promising prognostic marker for 
poor survival [101, 102].  However a study from 1,170 CRC patients demonstrates that 
patients with concomitant PIK3CA mutation in both exons 9 and 20 are associated with 
worse survival and individual mutation has no significant association with patient survival 
[103]. They also showed no significant interaction of PIK3CA mutation 





suggesting no significant addition of prognostic information from mutations in PIK3CA [104]. 
Despite all the controversies, PIK3CA mutation was shown to be a very promising predictive 
marker for adjuvant aspirin therapy. Regular use of aspirin after diagnosis was associated 
with superior clinical outcome and better survival in patients with mutated-PIK3CA colorectal 
cancer, but not among patients with wild-type PIK3CA cancer [105]. Another study from 
European retrospective consortium reports a PIK3CA mutation frequency of 14.5% in their 
dataset and exon 20 mutation in this gene was associated with a lack of response to 
Cetuximab in the KRAS wild type cohort [106]. Increased predictive power of PIK3CA 
mutation in KRAS wild type dataset has been validated in a recent study as well [107] 
indicating that stratifying the patients with  PIK3CA mutations, together with KRAS mutations, 
might be of benefit in clinical practice.   
1.8 MACC1 - A newly identified prognostic and predictive marker for CRC 
Our group identified a promising prognostic marker called Metastasis associated in colon 
cancer 1 (MACC1) through a genome-wide expression analyses carried out on primary, and 
metastatic tissues and normal mucosa of subjects with CRC. 
MACC1 mRNA expression in primary tumors directly correlated with metastasis formation 
and metastasis-free survival within a 12 year follow up. The five-year-survival rates dropped 
to 15% for patients with high MACC1 compared to 80% for patients with low MACC1 in their 
primary tumors [108]. MACC1 not only can be an effective biomarker for malignant tissues, 
but may also be helpful in differentiating high grade from low grade adenoma [108]. Further 
there have been numerous follow up studies confirming the prognostic value of MACC1 in 
metastasis and CRC recurrence [109-111]. MACC1 expression was also found to be 
correlated with relapse-free survival in patients with rectal cancer treated with chemo- and 
radiotherapy followed by surgery [112]. Apart from colon cancer, there have been numerous 
studies suggesting the importance of MACC1 as a biomarker in gastric, pancreatic, 
hepatobiliary, lung, ovarian, breast and glioblastoma cancers [113]. Recently our group also 
demonstrated diagnostic and prognostic power of MACC1 circulating transcripts in patient‟s 
plasma for predicting metastasis and overall survival [114]. Also in an integrative marker 
analysis study for KRAS, BRAF, MSI, SASH1 and MACC1 from stage II colon cancer 
patients, MACC1 outperformed all others and was the only independent parameter for 
predicting cancer recurrence [115]. Another study from patients with advanced hepatocellular 
carcinoma, high expression of MACC1 mRNA and the nuclear protein in the tumor predicted 
poor outcome of cryotherapy in these patients [116]. Also in liver metastases samples of 





intronic region of MACC1 is demonstrated to be a predictor for reduced overall survival in 
CRC patients [118]. Another SNP rs975263 in the coding region of the MACC1 gene was 
suggested to be associated with a shorter metastasis-free survival, especially for stage I or II 
patients and those who are younger than 60 years of age [119]. 
Taken together, MACC1 harbors a great potential to be used in clinics as a prognostic 
marker for the identification of high-risk patients and metastasis and can be used to predict 
cancer recurrence and therapy response. The following sections will describe in detail about 
MACC1 and the ongoing research focused on the tremendous potential of MACC1 in CRC 
carcinogenesis. 
1.8.1 The new gene MACC1: Discovery 
Going back to 2009, using differential display RT-PCR with colon mucosa, primary tumors 
and metastases of subjects with colon cancer, MACC1 was identified with no similarity to 
known genes [108]. The MACC1 gene is located on human chromosome 7 (7p21.1) on the 
minus strand. Interestingly, the nearest neighbor of MACC1 on chromosome 7p arm are 
TWISTNB, TWIST1 and ITGB8 which are known to be involved in tumorigenesis and 
metastasis of CRC [120, 121]. Among distant neighbors are genes for Met and HGF on the 
7th chromosome but 7q31.2 and 7q21.1 respectively. The unspliced primary MACC1 
transcript contains seven exons and six introns with a longest spliced mRNA of length 3,188 
nucleotides (GeneBank: AK131400.1). MACC1 encodes for a protein of 852 amino acids. 
The N-terminal region constituting 103 to 150 bp contains clathrin box, two Epsin 15 
Homology motif (EH) interacting sites, and an adaptor protein 2α (AP2α) binding site. 
Followed by this is a ZU5 domain involved in mediating protein-protein interaction. The 
remarkable C terminus possesses both an SH3 binding motif and a variant SH3 domain 
showing that this combination might result in the formation of homomeric or heteromeric 
dimers [122]. Our group also demonstrated that both the SH3 domain and SH3 binding motif 
are crucial for Met transcription and for the translocation of MACC1 into the nucleus [108]. In 
addition, MACC1 also possess two C terminal death domains, giving hints for its role in 
regulating apoptosis. Moreover, a phage display screening suggests MACC1 as binding 
partner for the proline-rich motif of human FasL (CD178) via its SH3 domain [123]. 
As already mentioned MACC1 expression was found to be directly correlated with 
metastases formation and metastasis-free survival but various other cellular and biological 





1.8.2 Role of MACC1 in CRC progression and metastasis 
MACC1 has been shown to induce cell migration, invasion, proliferation and colony formation 
in cell culture based assays from different solid cancer derived cells [108, 124-130]. The first 
cellular aspect of MACC1 associated metastasis was demonstrated by our group. Receptor 
tyrosine kinase Met was identified as the transcriptional target of MACC1 (Fig. 1.4) thereby 
shedding light on metastasis induced by MACC1 via HGF-Met-MAPK pathway [108]. In CRC 
patient-derived mouse xenografts, MACC1 showed better correlation with aggressiveness 
and unfavorable pathological parameters as compared with Met. In silico analysis based on 
the transcriptional binding sequence on the Met promoter, putative MACC1 target gene sets 
which correlate with high metastasis and aggressive tumors were predicted [131]. Further in 
vivo studies with different mouse models showed enhanced tumor growth and liver 
metastasis on transplanting MACC1 overexpressing tumor cells [108]. Transplantation of 
cells with high MACC1 expression treated with shRNA MACC1 led to reduction in tumor 
formation and metastasis in xenografted nude mice and SCID mice [132]. Mutation in SH3 
domain of MACC1 resulted in loss of all the biological functions in vitro and in vivo [108]. 
Furthermore there have been studies suggesting the association of MACC1 with EMT 
markers in patients with gastric cancer. The hallmark epithelial markers (E-cadherin and α-
catenin) were inhibited by MACC1, whereas mesenchymal markers Fibronectin, MMP2, 
MMP9, Vimentin and CD44) were shown to be up-regulated and the effects could be 
reversed with shMACC1 cells [128]. The mesenchymal markers help degrade extracellular 
matrix (ECM) and facilitate cell migration [133]. Another study from huh7 hepatocellular 
carcinoma cell line also suggested the association of MACC1 in inducing EMT via up 
regulating MMP2 and MMP9 [127]. In nasopharyngeal carcinoma, there has been a report 
showing association of MACC1 with phosphorylated-Akt expression and β-Catenin [129]. A 
very interesting study demonstrated three fold higher MACC1 in Lgr5-GFP high cells over 
low cells suggesting the association of MACC1 with intestinal stem cells [134]. However, 
these findings are still preliminary and need to be further validated in different solid cancer 
entities. To conclude, within the tumor progression model for CRC, MACC1 inflation at the 








Fig 1.4: Schematic model of MACC1 regulating HGF signaling. HGF translocate MACC1 from the 
cytoplasm to the nucleus where it binds to the Met promoter. This transcriptional activation of Met, 
thus forms a positive feedback looping hyper activating HGF-Met pathway and thus metastasis. 
Furthermore MACC1 is suggested to be a downstream target of MAPK.  Adapted from Arlt et al. [135] 
1.8.3 miRNAs associated with MACC1 
The concept of several noncoding RNA genes, miRNAs, in regulating metastasis is not new. 
Such miRNAs, termed as metastamir by Hurst et al. contributes to causing lethal metastasis 
[136]. In a miRNA profiling based study from human CRC‟s with and without liver metastasis, 
miRNA signatures were identified classifying patients for metastasis [137]. Further, a study 
displayed differential expression of miRNAs in CRC‟s and matched brain metastatic 
carcinomas [138]. These results suggested that miRNAs might be involved in liver 
metastasis of human CRC and can be used as prognostic tools as well. The first association 
of MACC1 with miRNA came from a study describing the role of MACC1 in mir-1 and Met 
network. They demonstrated that Met is significantly up-regulated by MACC1 only if it is 
coupled with mir-1 down-regulation [139]. Thus, concomitant mir-1 decrease and MACC1 
increase imparts Met associated metastatic behaviour of colon cancer cells. A little later, mir-
143 was identified as the first miRNA binding and regulating MACC1 and MACC1-induced 
cell motility. They reported that mir-143 might function as a metastamir by inhibiting cell 
migration and invasion via targeting MACC1 [125]. More studies are needed to validate the 
role of these miRNAs as independent biomarkers or to establish their possible role to 





1.8.4 Miscellaneous roles of MACC1 apart from cancer 
Besides cancer, MACC1 has been proposed to be associated with the development of other 
non-cancerous pathologies. Data from one group attributed the role of MACC1 to craniofacial 
development. This group used microarray analysis to catalogue gene transcripts involved in 
mouse face formation [140]. Among the candidates was the MACC1 gene which was 
validated using Morpholino (MO) based screening to be involved in a progressive and dose 
dependent loss of neural crest–derived cartilages [141]. Early in 2005, MACC1 (referred to 
as 7a5 earlier), was expressed in retinal cells ARPE-19 and Y79 as well as in neural retina 
and retinal pigments epithelium extracts [142]. There have been clues of MACC1 being 
responsible for maintaining pluripotency as predicted by neuron derived iPSC's screen using 
RNA-Seq. [143]. A study on a family from Pakistan with autosomal recessive non-syndromic 
hearing impairment (ARNSHI) led to the identification of novel locus DFNB90 mapped to 
chromosome 7 (7p22.1-p15.3). MACC1 was one among the candidate gene which resides in 
this locus. However on sequencing the candidate genes, no causal variant was identified 
[144]. Apart from the putative role of MACC1 in development, there might be a possibility of 
its link to migraine as depicted by a meta-analysis of genome-wide associations with respect 
to migraine. This analysis reports 32 SNPs with MACC1 being third highest in terms of its p 
value [145]. Similarly another genome wide screen came up with MACC1 SNPs (rs206184 
and rs6974002) to be involved in coronary artery stenosis [146]. In addition MACC1 might be 
involved in immune/inflammatory processes. MACC1 was found to be amongst 200 gene 
regions associated with multifactorial Crohn‟s disease [147]. Another hint for MACC1 being 
associated with inflammation was shown in a study which focused on the transcriptional 
effects of IFN γ or IL-4 treatment on subsequent TLR4 activation in mouse macrophages. 
MACC1 was one amongst the genes which was cooperatively up-regulated by IL-4 and LPS 
[148]. All these studies pin down the role of MACC1 in development and immunity in addition 
to cancer progression. However, more research needs to be done to address these 
additional features of MACC1. A MACC1 knock out animal if generated in the future might 















“Patients rarely die from the effects of a primary tumor; 90 percent of deaths from 
cancer are the result of metastases, of malignant cellular outposts proliferating far 
from the neoplastic mass that spawned them. They are barbarians, the colonist cells, 
co-opting all nutrients in their adopted organ and starving their normal neighbors of 
air, sugar and salts, and blocking traffic and clogging conduits, and finally, when their 
greed exceeds their easy grab, tearing open surrounding cells and feasting like 
cannibals on the meat of their fellows.”  
 























2. AIM OF THE STUDY 
 
The past few years have established MACC1 as a powerful prognostic and predictive marker 
for metastasis and metastasis free survival. In addition, these studies have emphasized the 
role of MACC1 in CRC progression. shRNA against MACC1 was shown to inhibit tumor 
formation and metastasis in xenografted mice models. Our present study along with the 
previously known studies, envisioned the importance of MACC1 inhibition. However the 
protein structure of MACC1 remains unknown and potential MACC1 protein inhibitors could 
not be generated. Besides, nothing was known about the promoter sequence and 
transcriptional regulation of this gene and thus no MACC1 transcriptional inhibitor has been 
reported so far. 
Thus, the main objectives of this study are as follows: 
 
 Identification of the MACC1 promoter and elucidation of its transcriptional regulation 
mechanism. This included identification and validation of the transcription factors 
binding to the MACC1 promoter. Additionally, to provide proof of principle by showing 
regulation of MACC1 expression and MACC1 induced motility by these transcription 
factors and to further address the significance of these transcription factors in tumor 
specimens with high MACC1 levels and metastasis formation. 
 
 Translation of the knowledge from the promoter studies to identify small molecule 
transcriptional inhibitor(s) of the MACC1 gene. This included evaluating these 
inhibitor(s) in vitro for the reduction in MACC1 expression and MACC1 associated 
motility. Further, the study included validating these inhibitor(s) in vivo for their ability 
















3. MATERIALS AND METHODS 
 
3.1 Cloning 
Genomic DNA (gDNA) was isolated from SW620 cells using QIAamp DNA Mini Kit (Qiagen). 
gDNA was PCR amplified using Pwo master mix (Roche) with a specific set of primers to 
obtain the desired insert. The PCR product was then purified by ethanol precipitation. DNA 
(PCR product as well as vector) was digested with FastDigest® Restriction Enzymes in 1x 
FastDigest® Buffer (both Fermentas) at 37 °C for 1.5 h. Digested DNA was separated by 
agarose gel electrophoresis at 100 V for 30 min in gels containing 1% w/v agarose 
(Invitrogen) in TAE-buffer (40 mM Tris, 1 mM Na2EDTA and 20 mM acetic acid, pH 8). DNA 
was then purified from the agarose gel using Invisorb® Spin DNA extraction Kit (Invitek) 
according to the manufacturer‟s instructions. Purified DNA was ligated in a 1:10 ratio of 
vector backbone and insert. Ligation was carried out with 0.25 U/µl T4 Ligase in 1x Ligase 
Buffer (both Fermentas) for 1 hat room temperature. Bacterial transformation was performed 
in DH5α™ chemically competent cells (Invitrogen) according to the manufacturer‟s 
instructions. Transformed bacteria were spread on selective agar plates and allowed to grow 
overnight at 37°C. DNA plasmid preparation from positive colonies was performed with 
Invisorb ® Spin Plasmid Mini Two (Invitek). Control digestion of plasmids followed by 
agarose gel electrophoresis identified positive clones. For preparing plasmids suitable for 
transfection, endotoxin-free plasmid DNA Maxi Prep was done using the JETSTAR 2.0 Maxi 
kit (Genomed) according to the manufacturer‟s instruction. Cloned constructs were 
sequenced for correct in frame orientation (Stratec Molecular). 
3.1.1 MACC1 promoter luciferase reporter constructs 
The MACC1 promoter region was PCR amplified using genomic DNA from SW620 cells as a 
template. Two different promoter fragments -1982 to -18 and -992 to -18 were generated 
using the primers listed in Table 3.1. PCR was performed using Pwo master mix with an 
initial denaturation at 94°C for 2 min, followed by 40 cycles of denaturation at 94°C for 30 s, 
annealing at 60°C for 30 s and extension at 72°C for 3 min. A final extension step was 
included at 72°C for 5 min. The PCR product was ethanol precipitated and digested with SacI 
and BglII restriction enzymes. The digested product was ran on gel, purified and cloned into 
SacI (5‟) and BglII (3‟) restriction sites of the pGL4.17 vector from Promega 
(pGL4.17/MACC1p-992 and pGL4.17/MACC1p-1992). All the restriction enzymes were fast 
digest enzymes from Fermentas. Control digests of plasmids with SacI and BglII identified 
positive clones. Plasmids were purified and sequenced as described in section 3.1.  




3.1.2 5’-deletion constructs of MACC1 promoter 
A series of different 5‟-truncated fragments of this -992 to -18 promoter region was created 
using different primers mentioned in Table 3.1 and cloned into the pGL4.17 vector using 
restriction enzymes (SacI, EcoRV and BglII), resulting in pGL4.17/MACC1p-811, pGL4.17/M 
ACC1p-582,   pGL4.17/MACC1p-426,   pGL4.17/MACC1p-206   and   pGL4.17/MACC1p-
133.  All constructs were sequenced as described earlier. 
 
Table 3.1: Primers used for generation of the MACC1 promoter-luciferase clones 
Primer      Sequence 
pGL4.17/MACC1p-1992 F      5‟-ACCGGAGCTCAGAAGGGATCCATAAATGCTGG-3‟ 
pGL4.17/MACC1p-992 F      5‟-ACCGGAGCTCTTTTTCTTTGTCACCATTCTGCCA-3‟ 
pGL4.17/MACC1p-811 F 
 








5‟- GGTTGATATCAGGGCAGTGAGGCACCTT -3‟ 
 






pGL4.17/MACC1p-1992 R 5‟-GCTTAGATCTCCCTGCTTCCTGAGCCAC-3‟ 
 
MACC1p-426 mut c-Jun F 
 
     5‟-CTTCAGCTCTGAATTGCCGAAAGAGAATCT-3‟ 
 
MACC1p-426 mut c-Jun R 
 
     5‟-AGATTCTCTTTCGGCAAT TCAGAGCTGAAG-3‟ 
 
MACC1p-426 mut Sp1 F 
 
     5‟-ACTCTAGCC ATACGCAATCTTCTGGTT TCG-3‟ 
 
MACC1p-426 mut Sp1 R 
 
     5‟-CGAAACCAGAAGATTGCGTATGGCTAGAGT-3 
MACC1p-426 mut C/EBP F 
 
     5‟-GCTGCATGAGGATTTGCGGGCATAAATATTTTTTAC-3„ 
MACC1p-426 mut C/EBP R      5‟-GTAAAAAATATTTATGCCCGCAAATCCTCATGCAGC-3‟ 
Underlined bold base pairs represent the nucleotides which have been mutated to generate mutated 
MACC1 promoter fragments. 
3.1.3 Site directed mutated constructs of the MACC1 promoter 
Site directed mutagenesis was performed using the QuikChange site directed mutagenesis 
kit (Stratagene) according to the manufacturer‟s instruction. The -426 to -18 reporter 
construct was used as template and a two base pair mutation in the binding site of each 
transcription factor AP-1, Sp1, C/EBP was inserted using primers with the mutated sequence 




as underlined and highlighted in bold,  Table 3.1. Plasmids with the expected mutations were 
sequenced to confirm the existence of the mutation. 
3. 2 Cell culture 
3.2.1 CRC cell lines 
Cell culture media, PBS and Trypsin/EDTA solution were obtained from Life Technologies. 
Cell culture plastic ware was obtained from TPP, BD Biosciences or Greiner BioOne. All 
human CRC cell lines originally from American Type Culture Collection used in our study are 
listed in Table 3.2. Cells were grown in RPMI-1640 (PAA Laboratories) supplemented with 
10% fetal bovine serum (FBS; Invitrogen). All cells were maintained at 370C in a humidified 
5% carbon dioxide incubator. Cells were trypsinized and split in a 1:4 ratio every 3-4 days. All 
cells were negative for mycoplasma, verified regularly using MycoAlert® Mycoplasma 
detection kit (Lonza) Authentication of the cell lines was performed by short tandem repeat 
(STR) genotyping at the Leibniz-Institut DSMZ (Braunschweig, Germany). STR genotypes 
were consistent with published genotypes for these cell lines. 
 
Table 3.2 Summary of all colorectal cancer cell lines used in this study 
 
Cell line Medium ATCC number 
Caco2 DMEM, 10 % FBS HTB-37 
DLD1 DMEM, 10 % FBS CCL-221 
SW48 RPMI 1640, 10 % FBS CCL-231 
SW480 RPMI 1640, 10 % FBS CCL-227 
SW620 RPMI 1640, 10 % FBS CCL-228 
HCT116 DMEM, 10 % FBS CCL-247 
   
  All cell lines are registered in the American type culture collection (ATCC).  
3.2.2 Derivative cell lines 
HCT116-MACC1p-Luc cells used in the high throughput screening were obtained by stable 
transfections of MACC1 promoter constructs in HCT116 cells. Briefly 1x106 cells were plated 
in a 10 cm dish. For each transfection, 5 µg of pGL4.17/MACC1p-992 orpGL4.17 empty 
plasmid and 15 µl Fugene HD (Roche) were incubated for 20 min in 500 µl OptiMEM at room 
temperature. Subsequently the transfection mixture was added to the cells of 70% 
confluence in a total volume of 10 ml DMEM medium. After 48 h, selection of positive 




transfected cells occurred by treating cells with 1 mg/ml neomycin. Antibiotics were 
continuously present and were removed only 24 h before the experiments to avoid their 
interference.HCT116-CMVp-Luc cells applied in the high throughput screening and for in vivo 
imaging experiments were obtained by transfection of HCT116 with pcDNA3.1-puro-Luc. 
Stable expression of transgene was controlled regularly by Steady GlowTM Luciferase Assay 
System (Promega) according to the manufacturer‟s instructions. 
SW620-shControl and SW620-shGIPC1 cells with stable knockdown of GIPC1 were 
obtained by transfection of sh Control and shGIPC1 plasmid (SABiosciences) in SW620 cells 
and positive clones were selected using neomycin treatment. Stable knock down was 
monitored via regular detection of GIPC1mRNA levels by qRT-PCR. All the derivative cell 
lines are mentioned in Table 3.3 and the plasmids used for generating these derivative cell 
lines are described in Table 3.4 
 
Table 3.3 Summary of derivative cell lines used in this study 
Cell line Medium 
HCT116-pGL4.17-Luc DMEM, 10 % FBS 
HCT116-MACC1p-Luc DMEM, 10 % FBS 
HCT116-CMVp-Luc DMEM, 10 % FBS 
SW620-shControl RPMI, 10 % FBS 
SW620-shGIPC1 RPMI, 10 % FBS 
3.3 Transfections and drug treatment 
3.3.1 MACC1 promoter transfections 
Transient transfections were carried out in 24 well culture plates using Fugene HD (Roche) 
as a transfection reagent. 75000 cells were plated per well.  For each transfection, 1 µg of 
pGL4.17 vector consisting of a MACC1 promoter fragment or pGL4.17 empty vector along 
with 100 ng of pGL4.74 Renilla luciferase plasmid (internal control) and Fugene were 
incubated for 20 min at room temperature, in 100 µl OptiMEM. This transfection mixture was 
then added to the cells of 70% confluence in a total volume of 500 µl RMPI 1640 medium. 










Table 3.4 Plasmids used for colorectal cancer cell transfection 
Plasmid Features 
pGL4.17-MACC1p-Luc MACC1 promoter driven firefly luciferase cDNA; neomycin 
resistance 
pcDNA3.1-puro-Luc CMV promoter-driven firefly luciferase cDNA; puromycin 
resistance 
pcDNA3.1-MACC1 CMV promoter-driven MACC1 cDNA; neomycin resistance 
pGeneClip-shGIPC1 U1 promoter driven shGIPC1; neomycin resistance 
 
3.3.2 siRNA transfections 
Predesigned siRNA‟s for c-Jun and Sp1 were obtained from Ambion, whereas for C/EBPα 
and C/EBPβ, siRNA‟s were obtained from Qiagen. For RNA interference experiments, 2x105 
HCT116 cells were seeded in a 6 well plate. After 24 h, cells were transfected with 50 nM 
siRNA targeting c-Jun, Sp1 or C/EBP using RNAiMAX lipofectamine transfection reagent 
(Invitrogen). 50 nM siRNA was diluted in 250 µl of OptiMEM and was gently mixed with 250 
µl of OptiMEM containing 7 µl of lipofectamine. The transfection mix was incubated for 20 
min at room temperature and then was added to the plate containing 2 ml of media. 
3.3.3 Drug treatment 
The small compound inhibitors Rottlerin and Lovastatin were obtained from Santa Cruz 
Biotechnology and stored in dark at -20°C. Both drugs were solubilized in dimethylsulfoxide 
(DMSO) for in vitro application. The stock solution of 10 mM was prepared fresh every two 
weeks and stored in small aliquots at 20°C to avoid freeze thawing. To exclude adverse 
effects caused by DMSO, control cells were always treated with the equal amount of solvent. 
In vivo, Rottlerin was administered as suspension in 1% DMSO in saline + 0.5% Tween80. 
3.4 High throughput screening 
HCT116 cells stably expressing MACC1 promoter ahead of luciferase gene (HCT116-
MACC1p-Luc) were seeded into white 384 well plates (Corning) using the Tecan automatic 
pipetting system. A compound library consisting of 30,000 compounds from Chembionet was 
used and then test compounds were added on to the plate containing cells. The treatment 
was carried out for 24h at a concentration of 5 µM per compound. Following treatment, the 
luciferase signal was measured using a Tecan microplate reader. In parallel, a selectivity 
screen to eliminate general luciferase inhibitors, was carried out using HCT116 cells stably 
transfected with the CMV promoter ahead of the luciferase gene (HCT116-CMVp-Luc cells). 
All the measurements were made in triplicates. The compounds which were able to reduce 




luciferase value by 50% by specifically acting via MACC1 promoter were shortlisted. 
Compounds showing best evidences for selectivity screen were further used for 
concentration response testing using triplicate wells per concentration with a concentration 
range starting from 0.097 µM to 50 µM. High throughput screening and all the parameters 
used in the screening are explicitly described in Table 3.5. 
3.5 Cell culture based in vitro assay 
3.5.1 Dual Luciferase reporter gene assay 
Cells transfected with MACC1 promoter constructs and Renilla plasmid were evaluated for 
luciferase activity 24 h post transfection using the dual luciferase reporter assay system from 
Promega. Cells were lysed with 100 µl passive lysis buffer and kept on shaker for 15 min at 
room temperature. 20 µl of this lysate was then transferred to a white bottom plate and firefly 
luciferase activity as well as Renilla luciferase activity was measured with a luminometer 
(Tecan infinite 200 PRO). The firefly luciferase values were normalized with Renilla values 
which account for variations in transfection efficiency and cell number. 
3.5.2 Boyden chamber assay 
Cell migration analysis was performed with Boyden chamber assay. Cells were co-
transfected with siRNA for c-Jun or Sp1 along with either pcDNA3.1 as vector control or 
pcDNA3.1/MACC1 using Lipofectamine 2000 for 48 h. The pcDNA3.1/MACC1 plasmid used 
in our study has been documented earlier [119]. After an overnight serum starvation of cells, 
the transfected cells (2.5x105 cells in 300 µl RPMI-1640 with 2% FBS) were seeded into each 
transwell chamber (Millipore). The transwells were pre-soaked with medium prior to the 
seeding of cells. Fresh medium was added to the bottom chamber with 10% FBS and cells 
were allowed to attach and migrate for 24 h. Afterwards cells that had migrated to the lower 
chamber were incubated in trypsin-EDTA and counted 9 times in Neubauer chambers. For 
monitoring migration in response to the drug treatment, serum starved HCT116 cells (3x105 
cells in 300 µl of drug containing RPMI-1640 with 2% FBS) were seeded into pre-soaked 
transwell chambers with pore size of 8 µm (Corning). 650µl of fresh medium with 10% FBS 
and drug was added to the bottom chamber. The cells that had migrated to the lower 
chamber were stained with DAPI and 4-5 random pictures per transwell were taken under 
fluorescent microscope and then the cells were counted manually from those pictures. 
 
 




Table 3.5: High throughput screening criteria 
Category Parameter Description 
Assay Type of assay Cell based Luciferase Reporter assay 
 Target MACC1 promoter 
 Primary measurement Luminescence 
 Key reagents  Steady glow reagent from Protégé 
 Assay protocol 1. Day1: cell seeding 5,000 cells/well in 
40 µl RPMI medium 
 
2. Day2: add compounds 5 µM (Tecan 
Wall E, 0.2 µl, fc0.5% DMSO) 
 
 
3. Day3:  
 
- Aspirate with Tecan/WallE_10µl left 
- Add 10µl steady-Glo luciferase 
reagent in MACC1_cell platesP1, mix, 
and centrifuge 
- Measuring Luminescence 500 ms 
integration time after 15 min 
incubation 
 
Library  Library size  30,000 compounds library 
 Library composition Drug like molecules and LOPAC compounds 
 Source Chembionet 
   
Screen Format 384 well type 
 Concentration tested 5 µM 
 
 Plate controls HCT116-pGL4.17 empty vector cells, 
and Untreated and DMSO treated cells 
 
 Reagent/ compound dispensing 
system compounds                                               
 
5 µM (Tecan WallE, 0.2 µl, fc0.5% DMSO) 
 Detection instrument and software  
 
                                                           
Tecan luminometer at integration time 
500m/s    
 
Tecan infinite PRO 
 Assay validation/QC                             Z score > 0.4 
 Correction factors                                1.48 
 




Hit criteria                                        Z score 
 Hit rate  
 Additional assay(s)                   
 
Counter/specificity screen with  HCT116-
CMVp-Luc cells    
 
 Confirmation of hit purity and 
structure 
Mass spec 




3.5.3 Cytotoxicity assay 
Analysis of cell cytotoxicity was performed with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT; Sigma Aldrich) assay. Briefly, 5x103 cells were seeded 
into 96-well-plates and allowed to adhere to the bottom of the wells for 24 h. The cells were 
exposed to different concentrations of a compound or its solvent for 24 h. MTT was added to 
a final concentration of 0.5 mg/ml and incubated for 3 h at 37°C in a humidified incubator.  
MTT was reduced to purple formazan crystals by the mitochondria of living cells and the 
decrease in metabolized MTT represented decreased cell number. Formazan crystals were 
dissolved in 150 µl of DMSO and the absorption was measured at 560 nm in the absorbance 
reader (Tecan infinite 200 PRO). Cell viability was determined by dividing the absorbance 
ratio of formazan crystals of treated cells by the ratio obtained from untreated cells which 
was defined as 100% cell viability. Each experiment was done at least two independent 
times, each performed in triplicates. 
3.5.4 Wound healing assay 
The wound healing assay was used to analyze directed cell migration. On day 0, 5x104 cells 
were seeded into cell culture inserts (ibidi) to create a wound. After appropriate attachment 
time (24 h), culture inserts were gently removed using tweezers. A wound of about 500 µm 
width was inflicted after removal of cell culture inserts. Subsequently, medium containing 
drug was added. The progress of wound closure was monitored daily and microphotographs 
of 10x and 40x magnification were taken with the Leica DM IL light microscope (Leica 
Microsystems) on day 0 and day 3. Each wound healing assay was performed two 
independent times each time in duplicates. 
3.5.5 Colony formation assay 
Analysis of anchorage-independent cell proliferation was achieved by soft agar colony 
formation assay. A bottom layer containing 0.5 % w/v agarose, RPMI 1640 medium, 10% 
FBS and inhibitor or solvent was added to a 6 cm Ø dish. Onto the solidified bottom layer a 
top layer was added containing 8x103 cells, 0.33 % w/v agarose, RPMI 1640 medium, 10% 
FBS and inhibitor or solvent. Cells were seeded as single cells into the soft agar and 
incubated in a humidified incubator at 37°C and 5% CO2 for 10 days. Colony formation was 
visualized by 10x magnification for an overview and 40x magnification for single colonies in 
the Leica DM IL light microscope (Leica Microsystems). Colony quantification was achieved 
by counting cell colonies of more than 4 cells in 12 squares of 1 µm2. 




3.5.6 Proliferation assay 
For determination of anchorage-dependent cell proliferation, 4x103 cells were plated into 96-
well-plates and were allowed to accommodate for 15 h, before treatment was started. Cells 
were treated daily for 4 days with inhibitor or solvent. For determination of viable cells, MTT 
was added to a final concentration of 0.5 mg/ml, incubated for 3 h, and dissolved in DMSO 
and kept for shaking for 15 minutes. The optical density (OD) was measured at 560 nm as 
mentioned earlier. Each cell proliferation experiment was performed in triplicates.  
3.6 Protein-DNA interaction based assays 
3.6.1 Chromatin Immunoprecipitation assay  
Chromatin Immunoprecipitation assay (ChIP) assay was performed using EZ ChIPTM kit from 
Millipore as per manufacturer‟s instruction. All the reagents were provided in the kit unless 
stated. Cells (2x106) were plated in 10 cm dishes. After 24 h, the cells were cross-linked with 
1% formaldehyde for 10 min at room temperature, lysed and sonicated to release chromatin. 
Cell lysates were sonicated for 25 pulses at 40% output and centrifuged at 10,000 rpm for 
10 min. Supernatant was collected in a new tube and diluted using dilution buffer and 
protease inhibitor. 1% of this solution was stored at 4°C until the elution step to be served as 
input control. 
The protein-DNA complexes were precipitated on addition of polyclonal antibodies for c-Jun 
(Millipore), Sp1 (Millipore), C/EBPα (Active motif), and C/EBPβ (Santa Cruz) to the chromatin 
solution obtained above, overnight at 4°C. Protein G beads were then added and incubated 
for another 2 h at 4°C.Non-bound protein was washed away twice with the Wash Buffers 
provided in the kit. The protein-DNA-complex was eluted from the beads with the elution 
buffer followed by centrifugation at 3,000 rpm for 1 min. Cross linking of protein and DNA 
was reversed at 68°C overnight and residual protein was digested by proteinase K at 55°C 
for 2 h. DNA was purified by column purification. The extracted DNA was subjected to PCR 
(28 cycles at 94°C for 30 s and 60°C for 30 s and 72°C for 1 min) with MACC1 promoter 
primers (pGL4.17/MACC1p-426 F and pGL4.17/MACC1p-1992 R). The PCR product was run on 
an agarose gel to visualize the precipitation of the MACC1 promoter. GAPDH was used as 
an unrelated gene to validate the specificity of binding observed. 
3.6.2 Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) was performed using the 
LightShiftChemiluminescent EMSA Kit from Thermo Scientific as per manufacturer‟s 




instruction. Briefly 2x106 cells were seeded in a 10 cm culture dish and incubated for 24 h for 
adhering to the surface. Nuclear extracts were prepared using NE-PER nuclear and 
cytoplasmic extraction reagent from Thermo Scientific as per manufacturer‟s protocol. 5‟-
labeled biotin oligonucleotides for the putative binding sites for AP-1, Sp1 and C/EBP were 
synthesized (Biotez, Table 3.6) and were annealed by heating both forward and reverse 
strands for 10 min at 95°C and letting it cool gradually in the water bath.In a total volume of 
20 µl, 5 µl of nuclear extracted protein was incubated for 30 min at room temperature along 
with 0.05 % w/v poly dI·dC, 0.5 mM Tris, 0.05 mM EDTA, 2.5 % v/v glycerol, 0.2 % v/v NP-
40, 5 mM MgCl2 and double-stranded biotinylated oligonucleotides containing the respective 
transcription factor binding site as present in the MACC1 promoter. Electrophoretic 
separation of the protein-oligonucleotide-complexes was performed in pre-cast Novex 6 % 
TBE gels (Invitrogen) and in TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.3) 
for 60 min at 100 V. Capillary transfer of the protein-oligonucleotide-complexes to the 
HybondTM-N nylon membrane (Amersham Biosciences) occurred in 20x SSC buffer (3 M 
NaCl, 300 mM Na3C6H5O7, pH 7) overnight. Cross-linkage of transferred DNA to the 
membrane occurred at 250 mJ/cm2 for 1 min in the FL-20-M FluoLinkCrosslinker (Bachofer). 
Visualization of biotin-labeled DNA was performed with LightShiftChemiluminescent EMSA 
Kit (Pierce) according to manufacturer‟s instructions. For the super shift assay, the respective 
antibody (described earlier) for the specific transcription factor was added before addition of 
the corresponding oligonucleotide and incubated for 30 min on ice, whereas 100 fold molar 
excess of unlabeled oligonucleotides were used in the competition experiments. 
3.7 Gene expression analysis 
3.7.1 RNA isolation and Reverse transcription 
Cells (3x105) were seeded in a 6 well plate and total RNA was isolated using Roboklon kit 
from Genematrix according to manufacturer‟s instructions. RNA was quantified (Nanodrop, 
Peqlab) and 50 ng of RNA was reverse transcribed with random hexamers in a reaction mix  
(10 mM MgCl2, 1X RT-buffer, 250 μM pooled dNTPs, 1 U/μLRNAse inhibitor, 2.5 U/μl 
Moloney Murine Leukemia Virus reverse transcriptase; all from Applied Biosystems).  
Standard dilutions from the reverse transcription of 250 ng of total RNA isolated from 
HCT116 cells was used for the standard curve. Reaction occurred at 42 °C for 15 min, 99 °C 
for 5 min and subsequent cooling at 5 °C for 5 min. Reverse transcripts were either stored at 
-20 °C or directly used for quantitative real-time PCR.  
 
 




Table 3.6: Oligonucleotide sequence used for EMSA 
 
Primer    Sequence 
  
AP-1 oligo F  
AP-I oligo R 
 
Sp1 oligo F 









C/EBP oligo F 
C/EBP oligo R 
 
 
AP-1 mut F 
AP-1 mut R 
 
 
Sp1 mut F 
















Underlined base pairs represent the nucleotides which have been mutated to generate mutated 
MACC1 promoter fragments. 
3.7.2 Quantitative real-time PCR 
The cDNA was amplified using SYBR Green dye chemistry using the light cycler 480 (Roche 
Diagnostics). SYBR green was obtained from Promega. Primers used for PCR were 
obtained from Biotez and are listed in Table 3.7. Each PCR reaction was performed in a total 
volume of 10 µl in 96-well-plates in the LightCycler 480.  The PCR protocol for SYBR green 
based qRT-PCR comprised a pre-incubation step at 95 °C for 2 min followed by 45 cycles of 
(a) denaturation at 95 °C for 7 sec, (b) annealing at 60 °C for 10 sec and (c) elongation at 
72 °C for 20 sec. Each qRT-PCR reaction was performed in duplicate and in parallel cDNA 
quantification of the housekeeping gene GAPDH was done for normalization. To control for 
primer dimers or unwanted PCR side products the melting curve was measured with a 
continuous temperature increase from 65°C to 95°C with a rate of 0.1 °C/sec. Data analysis 
was performed with LightCycler 480 Software release 1.5.0 SP3 (Roche Diagnostics). Mean 
values were calculated from duplicate qRT-PCR reactions. Each mean value of the 
expressed gene was normalized to the respective mean amount of the GAPDH cDNA. 




3.7.3 Protein extraction and quantification 
For total protein extraction, cells (2x105) were plated in 6 well plates, and 48 h after siRNA 
transfection the cells were lysed with RIPA buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 
1% Nonidet P-40, supplemented with complete protease inhibitor tablets; Roche Diagnostics) 
for 30 min on ice. Cell debris was pelleted at 14,000 rpm for 10 min at 4°C.The supernatant 
was transferred to a new tube, stored at -80°C or directly subjected to Western blot analysis. 
Protein concentration was quantified before samples were loaded for Western blot analysis. 
Quantification was performed with Bicinchoninic Acid (BCA) Protein Assay Reagent (Pierce) 
according to manufacturer‟s instructions using 2 mg/ml BSA solution for the standard curve 
[149]. BCA reaction was incubated at 37°C for 15 min and absorption was measured at 
560 nm in the absorbance reader (Tecan infinite 200 PRO). 
 






MACC1 R     
 
    5‟-TTCTTTTGATTCCTCCGGTGA-3‟ 
 






    5‟-GAAGATGGTGATGGGATTTC-3‟ 
 






    5'-CAGGTGGCACAGCTTAAACA -3' 
 






    5'-GCTCTGAACATCCAGCAAAA -3' 
 
    5'-CAGAGTTTGGAACAGCCTGA -3' 
 




    5'-CGGTGGACAAGAACAGCAAC3' 
 




C/EBPβ R                                            
    5'-CACAGCGACGAGTACAAGATCC-3' 
 
    5'-CTTGAACAAGTTCCGCAGGGTG-3' 
 
β-Catenin-F     5'-GTGCTATCTGTCTGCTCTAGTA-3' 
β-Catenin-R     5‟-CTTCCTGTTTAGTTGCAGCATC-3‟ 
G6PDH-F     5‟-ATCGACCACTACCTGGGCAA-3‟ 
  
G6PDH-R     5‟-TTCTGCATCACGTCCCGGA-3‟ 
Primers were applied to a final concentration of 250 nM. 





3.7.4 Western blot analysis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting was used to analyze protein expression levels. Protein extracts were diluted 
with PBS to obtain 40 µg of total protein in 1x NuPAGE® loading buffer and 10 % DTT. 
Protein samples were loaded onto pre-cast NuPAGE®Novex 10 % Bis-Tris Gels 
(Invitrogen).Protein electrophoresis occurred in running buffer 1x NuPAGE® MOPS at 200 V 
for 45 min within the XCellSureLock™ Mini Cell System. The pre-stained Spectra™ 
Multicolor Broad Range Protein Ladder (Fermentas) was used to determine band size.  
Semi-dry electrotransfer blotting of proteins onto the Hybond C Extra nitrocellulose 
membrane (Amersham Biosciences) occurred in blotting buffer (25 mM Tris-HCl, 
200 mMglycin, 0,1 % SDS, 20 % methanol, pH7.5) at 25 V for 25 min in the Trans-Blot® 
Turbo™ Blotting System (Bio-Rad). Quality of the protein transfer was analyzed by protein 
staining with Ponceau S solution (Sigma). The membrane was washed with TBS-T (50 mM 
Tris-HCl, 150 mMNaCl, 0.05 % Tween 20, pH 7.5) and blocked for 1 h at room temperature 
with blocking buffer (5 % milk powder in TBST). Membranes were then incubated overnight 
at 4°C with primary antibody followed by incubation for 1 h at room temperature with HRP-
conjugated secondary antibody, both antibodies diluted in TBST with 5% BSA. Antibody-
protein complexes were visualized with WesternBright ECL HRP substrate (Advansta) and 
subsequent exposure to CL-Xposure Films (Pierce). Immunoblotting for β-actin served as 
protein loading control.  
 
Table 3.8: Antibodies used for western blot analysis, their dilutions and their 
origins 
Target Dilution Antibody 
Primary antibodies 
anti-β-Actin  1:10000 mouse monoclonal IgG, Pierce 
anti-MACC1  1:1000 rabbit polyclonal IgG, Sigma 
Anti-c-Jun                                    1:1000          rabbit polyclonal IgG, Cell signaling 
Anti-Sp1 1:1000 rabbit polyclonal IgG, Cell signaling 
Secondary antibodies 
anti-rabbit-HRP 1:10,000 HRP conjugated antibody, Promega 
anti-mouse-IgG-HRP 1:10,000 HRP conjugated antibody, Pierce 
 
 




3.8 Tissue specimens 
This study was conducted on tissue specimens from 60 patients with CRC with informed 
written consent (approved by Charite Ethics Committee, Charite University medicine, Berlin) 
as described in our previous study [108]. The 60 subjects with stage 1-3 cancer (no distant 
metastases at the time of surgery) were previously untreated, did not have a history of 
familial CRC, did not suffer from a second tumor of the same or a different entity and 
underwent surgical R0 resection (complete resection with no microscopic residual tumor). 
Thereof, 23 patients developed distant metastases in the following twelve years. The follow-
up data of all patients was documented up to 14 years (with a median follow-up of 6.3 years) 
after diagnosis. Tumors were shock frozen in liquid nitrogen immediately after surgery. 
Cryosections were performed and every fifth section was stained with hematoxylin. Tumor 
cell areas were evaluated and marked by a pathologist. Tumor cells were removed from the 
unstained slides and RNA was extracted by using trizol reagent (Invitrogen) including a 
DNase step. RNA quality was proven (2100 Bioanalyzer, Agilent), and concentration was 
measured (RiboGreen RNA Quantitation Kit, Invitrogen). 
3.9 In vivo tumor formation and bioluminescence imaging 
All animal experiments were performed in accordance with the UKCCCR guidelines and in 
cooperation with Dr. Iduna Fichtner (MDC Berlin, Germany). Further, all animal experiments 
were approved by the State Office of Health and Social Affairs, Berlin, Germany under the 
G0289/13permit. 
3.9.1 In vivo dose-finding for Rottlerin 
For dose finding experiments, 6-week-old female non-obese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice were randomly assigned to 4 groups with 2 animals per 
group. Rottlerin treatment was performed daily by intraperitoneal injection (i.p.) of 1, 5 and 
10 mg/kg Rottlerin along with the respective amount of solvent as placebo. Body weight was 
analyzed daily to observe toxic effects of the drug. Mice were sacrificed at day 8.  
3.9.2 Intrasplenal tumor transplantation 
For intrasplenal transplantation 6-week-old female NOD/SCID mice (EPO GmbH) were used. 
Mice were anesthetized with 35 mg/kg Hypnomidate® (Jassen-Cilag) and the skin and 
peritoneum were laterally incised to exteriorize the spleen.HCT116-CMVp-Luccells were 
resuspended in PBS and kept on ice during the surgery. 3×106 of these cells were 




intrasplenically injected with a 27-gauge needle. The spleen was carefully placed back, the 
peritoneum was closed with Surgicryl ® absorbable suture and the skin was clamped twice.  
3.9.3 Analysis of metastasis formation in vivo 
Intrasplenically transplanted NOD/SCID mice were randomly assigned to 2 groups of 4 
animals. Treatment of animals started 24 h after cell transplantation. Mice were daily treated 
intraperitoneally with one dose of 5 mg/kg. Control animals received the corresponding 
amount of solvent. Mice were sacrificed at day 27 for ethical reasons. Spleen (as the 
transplantation site) and liver (as a metastasis target organ) were removed. The level of 
metastasis was evaluated by scoring considering both the number and the size of metastatic 
nodules (1 mm = score 1; 2 mm = score 8; 3 mm = score 27; 4 mm = score 64; 5 mm = 
score 125).  
3.9.4 In vivo bioluminescence imaging 
Intrasplenically transplanted SCID mice were randomly assigned to 2 groups of 4 animals 
each. Mice were treated intraperitoneally with daily doses of 5 mg/kg Rottlerin or solvent. For 
non-invasive bioluminescence imaging, mice were given Isoflurane gas anesthesia (TH. 
Geyer) every 3 days and received intraperitoneally 100 mg/kg D-luciferin (Biosynth) 
dissolved in PBS. Imaging was performed with the VisiLuxx Imager (Visitron Systems) with 
exposure times of upto 10 min. Metamorph software was used for color coding of the signal 
intensity (presenting a 256 gray scale) and for generating overlay pictures.   
3.9.5 Human MACC1 expression in murine xenograft tissue 
Spleen tumor tissue was shock frozen with liquid nitrogen after resection and stored at -
80°C. For isolation of mRNA, the tumor tissue was grinded under liquid nitrogen to a fine 
powder using previously cooled mortar and pestle. RL buffer was added to tissue slices and 
samples were sonicated for 10 pulses at 40 % output to assure complete cell lysis. RNA 
isolation and reverse transcription was performed as described in sections 3.7.1 and 3.7.2, 
respectively. Primers for quantification of MACC1 cDNA were designed to be specific to the 
human sequence of MACC1 excluding murine MACC1 cDNA to interfere with the 
measurements. 
3.10 Statistical analysis 
All calculations and statistics were performed with GraphPad Prism version 5.01. 
Comparison of two groups was done by Student‟s t-test. Comparison of a control versus 




several treated groups was performed by one-way analysis of variance (ANOVA) and 
Bonferroni post hoc multiple comparison. For correlation analysis, non-parametric Spearmen 
correlation test was used. All significance tests were two-sided, and P values less than 0.05 













































4.1 Identification of the MACC1 gene promoter 
4.1.1 MACC1 promoter lies within 992 bp upstream of the transcription start site 
The transcription start site (TSS) of the MACC1 gene has been already identified by our 
group using 5‟ RACE experiment as reported in our previous study [108]. To identify the 
MACC1 promoter, we cloned sequences upstream of the TSS (+1) of the longest known 
transcript (-18 to -992 bp and from -18 to -1992 to bp) into the promoter-less luciferase 
reporter vector pGL4.17. These constructs were then transfected into the HCT116, CRC cell 
line endogenously expressing MACC1. The promoter activity was measured after 24 h using 
the luciferase reporter gene assay. As shown in Fig. 4.1A, transfection of these two 
constructs, MACC1p-1992 and MACC1p-992 into HCT116 cells resulted in significantly 
higher promoter activity as compared with empty vector control (both P<0.0001) and no 
significant difference in transcription activity was seen between these two constructs. This 
finding suggested that the MACC1 promoter region encompassing nucleotides -992 to -18 bp 
contains all the information to drive transcription of the MACC1 gene in HCT116 cells. This 
MACC1 gene promoter sequence (Fig. 4.1B) has been submitted to GenBank (GenBank 








 -992 TTTTTCTTTGTCACCATTCTGCCATCTACTTACATTAGATGAATCCTTCTATTATGTTTC 
 -932 TGAACCCAGACCCAGCCAGGACTTGTCTCTATTCATTTTCTGGGCTGTGTCTAACAGGAG 
 -872 ATAATAGGCTAGAGAGAGATGCTGTATGAACAAATAGAGAAACACATTTGTTTTAAACAT 
 -812 TCTCTGTTGCTGATGTTGGAAAAAAATGTGAAACAATTATTGCACATTTCATTTCACTAA 
 -752 GTTTTACCTTTTTTCCCCTTTCCCCTAATTTTCTCTTTCTTGAATTTTGAACAAAATACA 
 -692 CAGAAGGAAAACACAAAACACAGAAATGGAAAGTAAAATGGAAGAAAATATCAAGAAAAC 
 -632 TTTATTCTTGCTTATATTTTAAAAGGCACATTTTAAAGTGTTATCTTAAAAATCCAGAGC 
 -572 ATTTTAGAAGATGAAATGCCAAAAGGTCTCCATTATGTCTATATGTCTATGTCTTTGAGT 
 -512 GACAATCACAGTGCTGATGTAGAGGGAAAGGGGGAACTAGTTAGACACTGTCACTCACCT 
 -452 GGGAAGGCTTTATTCACCTGTTCCACAGGGCAGTGAGGCACCTTCAGCTCTGAATCACCG 
 -392 AAAGAGAATCTGGTGGGGCAAGTTCCAGCTGCATGAGGATTTGCTTGCATAAATATTTTT 
 -332 TACTTATTGCTAACACTGAGGGTGCCTTCTTACTCCCTGGCAAACATTAAACCACTTTTA 
 -272 TTTCCTTTCATGGAAATAAGATTATATTTACAGATGGTTCTTAGATATACTCACCTGATT 
 -212 TTTTTTTAATTGCTTTTCCACCTGCTTCCCCTTTCTTCTTAGGGTGAAACTCTAGCCATA 
 -152 CGCCCTCTTCTGGTTTCGGGTGAGGAGCCTGAATTGTGGGTATCGTAGTTCTCTTGCCTT 
  -92 TTGGGGTTTCTAGTTGGGCAGCTTTGGAGCCACAGTGGTAGAACTTCAAGTCCCAGGTGG 
  -32 CTCAGGAAGCAGGG -18 
 
 
Figure 4.1 Identification of the MACC1 promoter. A) MACC1p-1992 and MACC1p-992 luciferase 
promoter constructs were co-transfected along with pGL4.74 Renilla plasmid in HCT116 cells. After 24 
h of transfection, luciferase activity was measured and was normalized to Renilla luciferase activity to 
correct for the variation in transfection efficiencies. Luciferase activity of the MACC1p-992 construct 
was set to 100% and activity of the other construct and empty vector alone was calculated and plotted 
as a percentage of this value. Results are shown as means ± SEM of three independent experiments 
performed in duplicates. B) Genomic sequence of the region containing the MACC1 promoter. The 
numbers indicate the base location relative to the start site of the first exon. 
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4.1.2 MACC1 minimal essential promoter domain lies within 426 bp upstream of the 
TSS 
To identify the minimal essential core promoter region within -992 kb, we cloned six different 
5‟-deletion constructs of the MACC1p-992 promoter fragment. These constructs were then 
transfected into HCT116 cells and luciferase activity was measured. Our data (Fig. 4.2 A) 
demonstrated that deletion of distal promoter fragment from -992 until -426 bp did not 
decrease the promoter activity significantly. However, further deletion of -426 to -18 bp 
resulting in -206 to -18 bp and -133 to -18 bp fragments lead to statistically significant 
decrease in the MACC1 promoter activity by 45% and 81% respectively. These results reveal 
that the region within -426 to -133 bp incorporate the crucial information to drive MACC1 
transcription and regulation and thus represents the core region of the MACC1 promoter. 
Data obtained in HCT116 cells was validated in an additional CRC cancer cell line, SW620. 
We transfected pGL4.17/MACC1p-992 andpGL4.17/MACC1p-426 constructs in SW620 and 
HCT116 cell lines (Fig. 4.2B). We observed no statistically significant differences between 
the two constructs in both of the cell lines further suggesting that MACC1p-426 construct 
possesses all essential information for the MACC1 transcription.  
Additionally, through ChIP assay, we showed the binding of RNA polymerase II to the 
MACC1 promoter (-426 to -18) suggesting the presence of the basal transcriptional 
machinery within the vicinity of this region (Fig. 4.2 C). We also compared human and mouse 
DNA sequences (http://pipeline.lbl.gov) corresponding to the MACC1 gene and their 5‟ 
flanking region. We observed two regions with high degree of conservation (71.4% and 
72.1%) immediately upstream of the TSS comprising the core region of the MACC1 
promoter, further establishing the importance of that region (Fig. 4.2 D). To summarize, we 
demonstrated that the MACC1 promoter lies within 992 bp upstream of the TSS. 426 bp 
upstream of the TSS constitutes the core region of the MACC1 promoter and is sufficient to 
drive the transcription of this gene. However it was essential to identify this long range 
promoter (MACC1p-992) as it might encompass trans-acting sequences, enhancer or 
silencer binding sequences or spatiotemporal information required for tissue specific or 
developmental stage specific expression of the MACC1 gene. 
 







Figure 4.2 Identification of the MACC1 core promoter region. A) Fragments of the MACC1 
promoter with deletions at the 5´ end and possessing a common 3´ end were obtained by PCR. The 
promoter fragments were then inserted into pGL4.17 and were transfected into HCT116 cells. 
Luciferase activity was measured as described earlier. B) MACC1p-992 and MACC1p-426 constructs 
were transfected into SW620 and HCT116 cells and luciferase activity was measured. Luciferase 
activity of the MACC1p-992 construct from HCT116 cells was normalized to empty vector and set to 
100% and activity of the other constructs were normalized to empty vector and plotted as a 
percentage of MACC1p-992 activity. C) HCT116 and SW620 cell chromatin was immunoprecipitated 
with a RNA Pol II antibody. Non-immune IgG and input DNA without any immunoprecipitation with 
antibody served as negative and positive controls respectively. After removal of crosslinks, the 
immunoprecipitated DNA was PCR amplified using a primer set encompassing the basal MACC1 
promoter region -426to -18 bp. The amplified DNA was analyzed by agarose gel electrophoresis. 
Results are shown as means ± SEM of three independent experiments performed in duplicates. D) 
Human and mouse DNA sequence corresponding to the MACC1 gene and its 5‟ UTR region were 
compared. The blue line indicates the MACC1 promoter and the peaks in pink show a region of high 
















4.1.3 The MACC1 promoter harbors functional binding sites for AP-1, Sp1 and C/EBP 
To identify transcription factors involved in MACC1 regulation, we performed in silico 
analyses of the MACC1 core promoter sequence to find putative binding sites for specific 
factors by comparing the results of three different programs: Matinspector 
(http://www.genomatix.de), Promo Alggen (http://alggen.lsi.upc.es/), and Transcription 
Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess). Examination of the 
core promoter sequence of MACC1 using in silico methods revealed binding sites for several 
putative transcription factors. We focused on AP-1, Sp1 and C/EBP transcription factor 
binding sites because of their well-established role in regulating genes involved in 
carcinogenesis (Fig. 4.3 A). Starting from the TSS, we found a GC box for binding of Sp1. 
Sp1 has been shown to interact with TATA-binding protein associated factors TAFs and 
other cofactors, which comprise basal transcription factors [150, 151]. Apart from that, many 
studies have reported the link between elevated levels of Sp1 in tumors and up-regulation of 
genes involved in metastasis and survival [152-156]. Furthermore the MACC1 promoter 
sequence was shown to have a CCAAT box for binding of C/EBPs that can recruit so-called 
co-activators, such as CBP, that can open up the chromatin structure, or recruit basal 
transcription factors [157]. Upstream of the CCAAT box, the promoter possesses a binding 
site for AP1, a well-known transcription factor which is involved in the regulation of genes 
contributing to differentiation, proliferation and apoptosis [158]. We determined the functional 
relevance of these DNA binding sites in the MACC1 promoter by mutational analysis. By 
mutating two bases (shown in bold, Fig. 4.3 A) of each transcription factor binding site, we 
detected a significant decrease in the MACC1 promoter activity. Mutation of AP-1, Sp1 or 
C/EBP sites reduced the activity of the MACC1 promoter to 63%, 46% and 55% respectively 
(all P<0.001) (Fig. 4.3 B, C and D), indicating the importance of these sites for the promoter 
function. Taken together, the MACC1 promoter is a eukaryotic promoter bearing typical 
promoter elements like a GC box and a CCAAT box along with an AP-1 binding site 
contributing together for the transcriptional activation of the MACC1 gene. 
 














Figure 4.3 Identification of functional binding sites 
for AP-1, Sp1 and C/EBP. A) Schematic representation 
of the MACC1 core promoter (-18 to -426 bp upstream 
of TSS) is shown. The MACC1 promoter harbors binding 
sites for various transcription factors shown in boxes as 
predicted by in silico programs. B),C),D) Transcription 
factor binding sites were mutated at two base pairs as 
shown in bold in (A) and the mutated promoter plasmids 
were transiently transfected along with the Renilla 
plasmids into HCT116 cells. After 24 h of transfection, 
luciferase activity was determined and normalized to 
Renilla values. Luciferase activity of wt construct was 
set to 100% and the activity of the other constructs were 
calculated and plotted as a percentage of this value. 
Empty represents pGL4.17 plasmid without promoter; wt 
Prom represents wild type MACC1 promoter and mut 
represents mutated MACC1 promoter. 
 
 




4.1.4 AP-1, Sp1 and C/EBP physically bind to the MACC1 promoter 
We next performed EMSA experiments to establish the binding of these transcription factors 
to the MACC1 promoter. Nuclear extracts from HCT116 cells were prepared and incubated 
with biotin labeled MACC1 promoter oligonucleotides. Binding for AP-1 (Fig. 4.4 A), Sp1 (Fig. 
4.4 B) and C/EBP (Fig. 4.4 C) was analyzed by gel shift assay. The biotin labeled 
oligonucleotides harboring AP-1, Sp1 or C/EBP binding sites were able to form complexes 
with their respective proteins from the nuclear extract. On further addition of unlabeled 
oligonucleotide, we observed disappearance of the shifts as evidenced by the ability of 
excess unlabeled probe to compete with complex formation. The specificity of band was 
further confirmed by addition of antibodies for c-Jun (is a constitutively active component of 
the AP-1), Sp1, C/EBPα and C/EBPβ eventually leading to disappearance of the shift. In 
addition, disappearance of complex formation using mutated oligonucleotides bearing two 
base pair mutation in the binding region further authenticated the specificity of the binding. 
These results have also been validated in SW620, another CRC cancer cell line. 
We further analyzed the physical interaction of the transcription factors AP-1, Sp1 and 
C/EBPs with the MACC1 promoter by ChIP assay. A clear band on amplification of immune 
precipitated chromatin through specific antibody with primers for the MACC1 promoter 
demonstrated that c-Jun, Sp1, C/EBPα and C/EBPβ bind to the MACC1 promoter (Fig. 4.4 
D). Taken together, the results from both ChIP and EMSA analyses in two different cell line 
models confirmed the physical binding of the transcription factors AP-1, Sp1 as well as 
C/EBPα and C/EBPβ to the MACC1 promoter.   






Figure 4.4 Identification of functional binding sites for AP-1, Sp1 and C/EBP. EMSA was 
performed with equal amounts of nuclear extracts from HCT116 and SW620 cells incubated with 5‟ 
biotin labeled MACC1 promoter oligonucleotides flanking binding sites specific for the three 
transcription factors: A) AP-1, B) Sp1, and C) C/EBPs. A reaction with 100x molar excess of unlabeled 
competitor sequence was also carried out indicating the specificity of the protein-DNA complexes. The 
reactions were analyzed by polyacrylamide gel electrophoresis. For supershift analysis, the nuclear 
extracts were incubated with biotin labeled oligonucleotides along with antibodies for c-Jun (A), Sp1 
(B), C/EBPα and C/EBPβ (C). Binding of the antibodies resulted in disappearance of the protein-DNA 
binding complex. D) Equal amounts of HCT116 and SW620 chromatin were immunoprecipitated with 
antibodies for c-Jun, Sp1, C/EBPα and C/EBPβ and were quantified by agarose gel electrophoresis, 
using a primer set specific for the basal region (-426 to -18 bp). Non-immune IgG and input DNA 
served as negative and positive control respectively. Moreover, as a negative control, 
immunoprecipitated DNA was amplified by a primer set specific for an off target region (GAPDH) 
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4.1.5 AP-1, Sp1 and C/EBP regulate MACC1 mRNA and protein level 
Until now, we established the binding of AP-1, Sp1 and C/EBP to the MACC1 promoter. 
Next, we wanted to understand the relevance of these transcription factors in governing 
MACC1 expression. So we employed RNAi strategy to knock down these transcription 
factors individually and assessed their effects on MACC1 expression at the mRNA as well as 
at the protein level. We first used qRT-PCR to confirm the target-specific predesigned 
siRNAs for their knockdown efficacy (Fig. 4.5 A). Based on this, we transfected these siRNAs 
into HCT116 cells and determined MACC1 mRNA expression by qRT-PCR. As shown in Fig. 
4.5 B, siRNAs for c-Jun, Sp1, C/EBPα and C/EBPβ significantly reduced MACC1 mRNA 
levels by 2 fold (P<0.01), 1.5 fold (P<0.05), 1.8 fold (P<0.01) and 3.4 fold (P<0.001), 
respectively, as compared to a scrambled siRNA control sequence. Consistent with the 
mRNA levels, MACC1 protein expression was also down-regulated by siRNA treatment with 
the target specific siRNAs. The data clearly supports that these transcription factors, directly 
or indirectly, play an important role in determining MACC1 mRNA and protein expression and 
are indispensable for MACC1 regulation. 
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Figure 4.5 Implication of c-Jun, Sp1 and C/EBP in regulating MACC1 expression at the mRNA 
and the protein levels. siRNA knock-down was done to assess the effect of the transcription factors 
c-Jun, Sp1, C/EBPα and C/EBPβ on the MACC1 expression levels. HCT116 cells were transfected 
with siRNAs for each transcription factor. 48 h after transfection, total RNA was extracted, reverse 
transcribed and quantified by real time PCR. A) siRNA knock-down efficacy was validated for their 
respective target. Results are calculated as percentage of the untreated samples. B) Effect of siRNA 
on MACC1 expression. For MACC1 mRNA analysis, the data is normalized to GAPDH. Results are 
shown as means ± SEM of three independent experiments. For MACC1 protein analysis, cells 
transfected with siRNAs were harvested 48 h post transfection, and lysed in RIPA lysis buffer and the 
cell lysates were immunoblotted for MACC1 and β-Actin. A representative blot of three independent 
experiments is shown. 
 
4.1.6 AP-1 and Sp1 knock-down abate MACC1-induced migration 
MACC1 is a gene involved in CRC metastasis. MACC1-induced migration has already been 
described in HCT116 cells [119]. In order to ascertain the role of these transcription factors 
on MACC1-induced cell motility, we determined their effect on cell migration following knock 
down. HCT116 cells treated with siRNA for c-Jun or Sp1 showed significant inhibition of cell 
migration to 58% and 57% of control (both P < 0.01), respectively (Fig. 4.6 A). The knock-
down of C/EBPα however, did not result in significant changes in migration (P= 0.482, data 
not shown) and was therefore not followed further together with C/EBPβ because of the 
opposing transcriptional effects driven by LAP and LIP, C/EBPβ isoforms. To address if the 
decreases in migration caused by AP-1 and Sp1 were at least partially driven via decrease in 
MACC1 expression, we designed rescue experiments employing HCT116 cells co-
transfected with siRNA for c-Jun or Sp1 along with either pcDNA3.1 or pcDNA3.1/MACC1 
plasmid (Fig. 4.6 B). Overexpression of ectopic MACC1 rescued the effect of transcription 
factor knock-down-induced low migratory capability. In summary, AP-1 and Sp1 siRNA 
treatment restricted the migratory capabilities of HCT116 cells and the ectopic expression of 
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MACC1 was able to overcome AP-1 and Sp1-mediated migratory inhibition demonstrating 




Figure 4.6 Migratory abilities of AP-1 and Sp1 siRNA treated cells. A) HCT116 cells were co-
transfected with pcDNA3.1/empty plasmid and si control or siRNA for c-Jun or Sp1 for 48 h. Cell 
migration was counted using Boyden chamber assay and expressed as fold over si control treated 
cells. B) For rescue experiment, HCT116 cells were co-transfected with pcDNA3.1/MACC1 plasmid 
and siRNA for c-Jun or Sp1 for 48 h and cell migration was counted. Each migration assay was 
performed in triplicates and average of two independent experiments was plotted in the graph. ns 
represent data is not significant. 
 
4.1.7 AP-1 and Sp1 levels correlate with the MACC1 expression in human colorectal 
tumors 
To evaluate the correlation of AP-1 and Sp1 with MACC1 in clinical specimens of CRC, we 
used RNA from patient samples described in our previous study [108]. All patients underwent 
surgical R0 resection and showed no distant metastasis at the time of surgery and neither 
had they any history of familial CRC, or a second tumor of the same entity. We performed 
qRT-PCR for MACC1, c-Jun and Sp1. By using Spearman correlation method, we found a 
positive correlations between MACC1 and c-Jun (r = 0.5897) as well as between MACC1 
and Sp1 (r = 0.5153) indicating positive statistical dependence of two variables with each 
other (Fig. 4.7 A). We also looked for the biological dependence of AP-1 and Sp1 on 
MACC1. Thus, we classified the patients with low MACC1 expression and high MACC1 
expression using the median cut-off values. We then determined c-Jun and Sp1 levels in the 
two cohorts. Remarkably, we found that the tumors with low MACC1 expression also showed 
low expression of both c-Jun and Sp1, whereas high MACC1 expressers showed elevated 
level of c-Jun and Sp1 (P = 0.0007 and P = 0.02, respectively), (Fig. 4.7B). Furthermore, 
patients who developed metachronous metastases were shown to have significantly more c-
Jun and Sp1 levels compared with those that did not develop metastasis over 12 years (P = 
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0.01 and P = 0.001, respectively), (Fig. 4.7 C). Our data indicates that in the clinical setting, 













Figure 4.7 Correlation of MACC1 levels with AP-1 as well as Sp1 levels in colorectal tumors. 
qRT-PCR was performed on cDNA obtained from colorectal primary tumors (n = 60, stages 1-3) with 
23 patients that developed distant metastases in the following twelve years. A) Spearman correlation 
coefficient analysis for MACC1 and c-Jun as well as for MACC1 and Sp1 was done with non-
parametric data obtained from qRT-PCR results and correlation coefficient „r‟ was calculated. B) Box 
plot analyses comparing c-Jun as well as Sp1 levels among the low MACC1 and high MACC1-
expressing tumors. C) Box plot analyses comparing c-Jun as well as Sp1 levels among those tumors 
that did not metastasize (w/o metastasis) or that developed metastases metachronously. All qRT-PCR 






























4.2 GIPC1 as a novel potential transcription factor regulating MACC1 
4.2.1 GIPC1 silencing down regulates MACC1 expression 
GIPC1, a cytoplasmic scaffold protein with a PDZ domain, binds to numerous proteins and is 
involved in multiple biological processes, including cell migration. Our aim was to evaluate 
whether GIPC1 reduces migration by altering the levels of MACC1. Therefore, we made 
stable SW620 cell line with knocked-down GIPC1 (SW620-shGIPC1) using shRNA 
constructs. shRNA scrambled sequence was used as a control. We isolated RNA from these 
two cell lines and measured MACC1 mRNA expression by qRT-PCR (Fig. 4.8). We observed 
a 50% decrease in MACC1 expression in SW620-shGIPC1 cells as compared to SW620-
shControl cells suggesting the association of GIPC1 with MACC1. 
 
 
Figure 4.8 Effect of GIPC1 knock-down on MACC1 expression. shRNA transfection was done to 
knock down GIPC1 in SW620 cells. Stable clones were picked and validated. Total RNA was isolated 
from these cells, reverse transcribed and quantified using real time PCR. The data is normalized for 
G6PDH. Results are shown as means ± SEM of two independent experiments performed in duplicate. 
4.2.2 GIPC1 regulates the MACC1 promoter 
We observed that knock down of GIPC1 leads to reduced MACC1 expression. We then 
evaluated whether this effect mediated by GIPC1, is through regulating the MACC1 promoter 
activity. We transfected SW620-shControl and SW620-shGIPC1 cells with the full length 
MACC1-promoter luciferase construct (MACC1p-992) or empty vector alone. 24 h after 
transfection, we measured the luciferase activity. We found 48% decrease in the MACC1 
activity in GIPC1 knock down cells (Fig. 4.9 A) indicating the possible interaction of GIPC1 
with the MACC1 promoter. We were inquisitive about the region where it binds on the 
MACC1 promoter. So we transfected our previously described 5‟ truncated MACC1 promoter 
deletion constructs in SW620-shControl and SW620-shGIPC1 cells and calculated the 
reduction in the MACC1 promoter activity. We detected no significant reduction in MACC1 
promoter activity among different promoter constructs (Fig. 4.9 B) suggesting that the 









Figure 4.9 Effect of GIPC1 on the MACC1 promoter activity. A) MACC1 promoter luciferase 
reporter construct was co-transfected along with pGL4.74 Renilla plasmid in SW620-shcontrol and 
SW620-shGIPC1 cells. After 24 h of transfection, luciferase activity was measured and was 
normalized to Renilla luciferase activity to correct for the variation in transfection efficiencies. 
Luciferase activity from the SW620-shcontrol cells was set to 100%. B) Fragments of the MACC1 
promoter with deletions at the 5‟ end and possessing a common 3‟ end were inserted into pGL4.17 
and were transfected into SW620-shGIPC1 and SW620-shControl cells. Luciferase activity was 
normalized to Renilla values and expressed as percentage reduction of luciferase activity in SW620-
shGIPC1 as compared with SW620-shcontrol cells.  
 
4.2.3 GIPC1 physically interacts with the MACC1 promoter 
To demonstrate the physical binding of GIPC1 to the MACC1 promoter, we performed an 
EMSA assay. We designed biotin labeled oligonucleotides corresponding to the first 60 bp 
from TSS in the MACC1 promoter. On incubating 5‟ labelled MACC1 promoter fragment with 
nuclear extract from SW620 cell line, we observed DNA-protein complex formation which 
disappeared on adding 100 fold molar excess of unlabeled promoter fragment. The 
specificity of the complex was determined by addition of an antibody for GIPC1 which led to 
a decrease in the intensity of the specific shift (Fig. 4.10 A). 
Additionally, we analyzed the specific physical interaction of GIPC1 with the MACC1 
promoter by ChIP assay. A clear strong band was seen on amplification of immune 
precipitated chromatin by GIPC1 antibody with the primers for the MACC1 promoter 
(Fig. 4.10 B). Taken together, the results from both ChIP and EMSA analysis confirmed the 
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Figure 4.10 GIPC1 binds to the first 60 bp of the 
MACC1 promoter. A) 5‟ end biotin labeled 
oligonucleotide corresponding to MACC1 promoter 
were incubated alone as well as with nuclear 
extracts from SW620 cells along with 100x molar 
excess of unlabeled competitor sequence to 
indicate specificity of the protein-DNA complexes 
or with the antibody specific for GIPC1. The 
reactions were analyzed by polyacrylamide gel 
electrophoresis. N.S. indicates non-specific 
complex. B) SW620 chromatin was 
immunoprecipitated with antibodies for GIPC1 
antibody and quantified by agarose gel 
electrophoresis, using a primer set specific for the 
MACC1 promoter and GAPDH. Non-immune IgG 
and input DNA without any immunoprecipitation 
with antibody served as negative and positive 
controls respectively. 
 




4.3 Identification of small molecule transcriptional inhibitors of MACC1 
4.3.1 High-throughput screening led to the identification of small molecule 
transcriptional inhibitors of MACC1 
High-throughput screening (HTS) is a state-of-the-art technique in the field of drug discovery. 
Thus, in collaboration with Dr. Jens Von Kries (MDC, Berlin), we carried out a HTS using a 
Chembionet library of more than 30,000 compounds to identify small molecule inhibitors 
targeting the MACC1 gene promoter. The design of the screening process and downstream 
deconvolution strategy has been represented diagrammatically, followed by the outcome of 
the screen. Information on the novel inhibitors discovered and their behavior in dose-
dependence assays has also been provided, leading ultimately to the identification of 
Rottlerin and Lovastatin as the MACC1 transcriptional inhibitors of choice for further study. 
4.3.1.1 Pilot scale study led to design and optimization of the screening strategy 
We selected a cell based, luciferase-reporter assay to identify transcriptional inhibitors of 
MACC1. As described earlier, MACC1 promoter was cloned upstream of the luciferase gene 
in the pGL4.17 plasmid. (Fig.4.11 A).Herein, we transfected HCT116 cells with this construct, 
to generate a cell line stably expressing MACC1 promoter integrated with the luciferase 
gene. The selection of stable cell line was based on G418 resistance carried over by the 
pGL4.17 plasmid. As a negative control, pGL4.17 plasmid without any promoter before the 
luciferase gene was used. 
In order to establish a cell-based assay for HTS to identify small molecule MACC1 
transcriptional inhibitors, a large number of assay parameters were needed to be optimized 
first in a pilot scale done manually, followed by an assay transfer to a robotic system. These 
parameters included different 384-well plate formats (white opaque or clear bottom), DMSO 
concentrations, cell number, integration time for measuring luminescence and an optimal z 
factor (accounting for the suitability of experimental design, working positive and negative 
controls to be used for HTS). After repeating the assay with each of these variable 
parameters mentioned above, we finally optimized the screening for 5000 cells per plate in a 
white opaque 384-well plate with a moderate to good z factor ranging from 0.4 to 0.6 for the 
final screening. Further we selected integration time of 500 ms for luciferase measurement. 
Fig. 4.11 B  depict optimization of DMSO concentration to be used for drug treatment in the 
HTS after finalizing the cell number and integration time of 5000 cells and 500 ms 
respectively.  As shown in table, increase in DMSO concentration from 0.25% to 0.5% led to 
a slight increase in the promoter activity and therefore we restricted ourselves to a minimum 
possible concentration of 0.25%. Then we ran a test plate (assay transfer, Fig. 4.11C) with 




DMSO treated empty vector cells (negative control, depicted in red) in the first column and 
DMSO treated MACC1 promoter cells (positive control, depicted in blue) in the second 
column as shown in Fig. 4.11 C, and performed drug treatment with few inhibitors on rest of 
the plate having MACC1 promoter cells followed by luciferase assay after 24 h to measure 
MACC1 promoter activity. Our test plate worked efficiently and potential hits were found as 
indicated by reddish-brown squares. 
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Figure 4.11 Design and optimization for the luciferase based screening process. 
A) Schematic representation of the reporter system used in the high-throughput screening. The 
expression of firefly luciferase gene was regulated by the MACC1 promoter (-18 to -992 bp upstream 
of the TSS). B) Three 384-well plates were seeded with MACC1p-992-LUC cells (in blue) and LUC cell 
without any promoter (in red). Cells were then treated with or without DMSO (0.25% and 0.5%) for 24 
h and luciferase activity were measured as shown in the table. Mvpos represent mean value of 
MACC1 promoter cells, Mvneg represents mean value of empty vector cells, Sd represents standard 
deviation. C) Assay transfer with selected inhibitors as a test run wherein, red column contains 
pGL4.17 cells without any promoter treated with DMSO, blue column represents MACC1p-992-LUC 
cells treated with DMSO and rest of the green columns represent MACC1p-992-LUC cells treated with 
test compounds (left plate). Right plate represents MACC1 promoter driven luciferase activity in a 
scale from orange to green, orange being the minimum and green representing basal luciferase value 
and blue representing maximum luciferase activity. 
4.3.1.2 Identification of 97 novel small molecules as MACC1 transcriptional inhibitors 
For carrying out HTS, HCT116-MACC1p-992-LUC CRC cells stably expressing a human 
MACC1 promoter-driven luciferase reporter gene construct were used to screen the 
Chembionet library of more than 30,000 compounds which includes 1280 compounds from 
Sigma LOPAC library for identifying potential MACC1 inhibitors. In the primary screen, using 
5 µM concentration of each compound, we identified 542 compounds that inhibited MACC1 
promoter-driven luciferase expression by greater than 50% as compared to solvent treated 
control cells (schematic representation shown in Fig. 4.12 A). These 542 compounds were 
then subjected to a selectivity screen with HCT116-CMVp-Luc cells, wherein luciferase 
reporter gene is driven by CMV promoter instead of the MACC1 promoter. The compounds 
which inhibited luciferase expression with CMV driven cells by greater than 75% were 
considered as non-specific luciferase inhibitors or cytotoxic compounds leading to a 
decrease in the promoter activity. Out of 542 compounds, 445 compounds were found to 
inhibit CMV promoter driven luciferase expression and thus, were eliminated. Therefore, we 
were left with 97 effective compounds, which included 7 pharmacologically active 
compounds from LOPAC library and 90 novel chemical compounds. To confirm the inhibitory 
potential of the remaining 97 effective compounds and to establish the concentration 
response curves, the 97 compounds were titrated using 10 two fold serial dilutions starting 
with the highest concentration of 50 µM and luciferase assay was performed. On the basis of 
curve properties (Hill coefficient, Chi squared values and IC50 values), solubility and purity of 
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the drug, selectivity screen comparison, information on known biological targets, known 
functions and Z score, two out of seven pharmacologically active hits, Rottlerin and 






Figure 4.12 Schematic representation of high-throughput screening. A) Diagrammatic 
representation of the screening process. MACC1 promoter expressing cells were screened with 
chembionet compounds in a 384-well plate format. Screening consisted of primary screening followed 
by a selectivity screen and finally concentration-response assays with the potential hits. B) Heat map 
of a representative plate from a primary screen where red color represent minimum promoter activity 
and blue color represent maximum promoter activity. C) A scatter plot representing selectivity screen 
with 542 compounds. Cut off window of 50% was set for MACC1 promoter activity and 75% for CMV 
promoter activity and 97 compounds were then selected which decreased MACC1 promoter activity by 
more than 50% and CMV promoter to not more than 75%. 
 
4.3.1.3 Rottlerin and Mevastatin inhibit MACC1 promoter activity  
In concentration response assay for measuring MACC1 promoter activity, Rottlerin showed 
inhibition of luciferase activity from concentration of 0.78 µM onwards and Mevastatin 
A 
B C 




showed inhibition of luciferase activity at 1.56 µM and higher concentrations. We next wanted 
to evaluate whether this decrease in promoter activity is contributed by decrease in cell 
number, therefore, we performed a MTT assay to assess the effects of these drugs on cell 
viability. Rottlerin reduced cell viability at 6.25 µM and higher concentrations whereas 
Mevastatin reduced cell viability at 12.5 µM and higher concentrations (Fig. 4.13). Thus, the 
concentration-response assays confirmed that Rottlerin and Mevastatin inhibit MACC1 
promoter-driven reporter gene expression at non-cytotoxic concentrations and thus, we 
selected them for further studies as potential small molecule MACC1 transcriptional 
inhibitors. 
 
Figure 4.13 Identification of Rottlerin and Lovastatin as MACC1 transcriptional inhibitors via      
high-throughput screening. HCT116-MACC1p-Luc cells were treated with 10 two-fold serial dilutions 
of Rottlerin (A) and Mevastatin (B) for 24 h, starting with 50 µM concentration. Luciferase activity was 
determined using steady glow luciferase reagent and normalized to untreated cells. Cell viability was 
measured independently using MTT assay. Results are shown as means ± SEM of two independent 










































































4.3.2 Small molecule inhibitors restrict MACC1 expression 
4.3.2.1 Rottlerin and Mevastatin inhibit MACC1 expression in a concentration 
dependent manner 
To determine the ability of the small molecule inhibitors to reduce endogenous MACC1 
expression, HCT116 cells were treated with increasing concentrations of Rottlerin or 
Mevastatin for 24 h. Rottlerin treatment reduced the MACC1 mRNA level in a concentration-
dependent manner (Fig. 4.14 A). At a concentration of 2.5 µM, Rottlerin showed more than 
60% reduction in the endogenous MACC1 mRNA and MACC1 protein level compared to the 
solvent-treated control.  
Similar to the effects seen for Rottlerin, increasing concentrations of Mevastatin also inhibited 
MACC1 mRNA expression in a concentration-dependent manner (Fig. 4.14 B). A small 
reduction by 26% in the MACC1 mRNA level was seen when HCT116 cells were treated with 
2.5 µM.  Treatment with 5 µM Mevastatin significantly restricted the MACC1 mRNA level to 
less than 50% of the solvent-treated control. Additionally, the reduction in MACC1 protein 









Figure 4.14 Effect of Rottlerin and Mevastatin on MACC1 expression. HCT116 cells were treated 
with increasing concentrations of Rottlerin (A) or Mevastatin (B) for 24 h and MACC1 mRNA and 
protein expression was determined by qRT-PCR and Western blot analysis, respectively. Effective 
MACC1 inhibitory concentration of Rottlerin is shown in black bar and for Mevastatin is shown in grey 
bar. Data represent means ± SEM from three independent experiments.  
4.3.2.2 Lovastatin inhibits MACC1 expression in a concentration dependent manner 
Due to severe toxicity profile in clinical trials, Mevastatin was never introduced in the market. 
The first class of statins that entered the market and got FDA approval was Lovastatin [159]. 
Therefore, we wanted to know whether Lovastatin (a FDA approved analogue of Mevastatin) 
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has the same effect on MACC1 as Mevastatin. We performed a concentration response 
curve using 10 two-fold serial dilutions of Lovastatin as performed earlier for other 
compounds and analyzed its effect on cell viability and luciferase activity in HCT116-
MACC1p-Luc cells. Lovastatin inhibited luciferase activity at 0.39 µM and higher 
concentrations and reduced viability at 3.125 µM and higher concentrations (Fig. 4.15 A).  
Furthermore, to study the effect of Lovastatin on MACC1 expression, we treated HCT116 
cells with increasing concentrations of the inhibitor as done previously. Similar to Mevastatin, 
treatment with 5 µM of Lovastatin significantly reduced MACC1 mRNA levels by 62% as 
compared to solvent-treated control (Fig. 4.15 B). Additionally, treatment with Lovastatin 
induced a clear decrease in MACC1 protein level as demonstrated by western blotting. 
Altogether, these results demonstrate that Lovastatin and Mevastatin have similar potential 
as MACC1 inhibitors. Therefore, considering that, Lovastatin is accepted for therapeutic use 
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Figure 4.15 Effect of Lovastatin on MACC1 
promoter activity and expression. A) HCT116-
MACC1p-Luc cells were treated with 10 two-fold 
serial dilutions of Lovastatin for 24 h, starting with 
a 50 µM concentration. Luciferase activity was 
determined using steady glow luciferase reagent 
and normalized to untreated cells. Cell viability 
was measured independently using MTT assay. 
Results are shown as means ± SEM of two 
independent experiments performed in 
triplicates. B) HCT116 cells were treated with 
increasing concentrations of Lovastatin for 24 h 
and MACC1 mRNA and protein expression was 
determined by qRT-PCR and Western blot 
analysis, respectively. Data represent means ± 
SEM from three independent experiments. 
 




Our results (Fig. 4.14 and Fig. 4.15) demonstrate that Rottlerin and Lovastatin can reduce 
MACC1 mRNA and protein levels in a dose dependent manner. For further experiments, a 
drug concentration with a minimal effect on cell viability and a maximum effect on MACC1 
expression inhibition had to be selected. Therefore, a concentration of 2.5 µM for Rottlerin 
and 5 µM for Lovastatin was chosen for all further experiments.  
4.3.2.3 Rottlerin and Lovastatin inhibit MACC1 expression in a time dependent manner 
After evaluating the effective concentrations of Rottlerin and Lovastatin for inhibiting MACC1 
expression, the time dependent effect of these inhibitors on the MACC1 expression was 
analyzed. After 12 h exposure of HCT116 cells to a single dose of 2.5 µM Rottlerin, the 
MACC1 mRNA was significantly reduced to less than 50% of the solvent-treated control 
(Fig. 4.16 A). After 18 h, the MACC1 mRNA expression was reduced to 26% of the solvent 
treated cells that persisted until 62 h beyond which the cells could not be harvested due to 
the depletion of nutrients in the media. Thus, treatment of HCT116 cells with a single dose of 
2.5 µM of Rottlerin was sufficient to reduce the MACC1 mRNA to less than 30% of solvent-
treated control cells for at least 62 h. In agreement with the mRNA profile, reduction in the 
MACC1 protein was also detected 12 h post treatment with 2.5 µM of Rottlerin which stayed 
until 62 h following a single dose. 
Similarly, on analyzing the kinetics underlying the Lovastatin-mediated inhibition of the 
MACC1 expression, we found that a single dose of Lovastatin reduced the MACC1 
expression in a time dependent manner. After 12 h treatment of HCT116 cells with 5 µM of 
Lovastatin, the MACC1 mRNA level was already significantly reduced to 56% of the solvent-
treated control cells, which further decreased to 16% at 48 h. This was followed by a very 
slight increase at 62 h (Fig. 4.16 B). Reduction in MACC1 protein was observed 24 h post 
























Figure 4.16 Time dependent kinetics of Rottlerin and Lovastatin on MACC1 expression. HCT116 
cells were treated with a single dose of 2.5 µM Rottlerin or 5 µM Lovastatin for the time indicated. 
MACC1 mRNA and protein was analyzed by qRT-PCR and Western blot, respectively. Data represent 
mean ± SEM from three independent experiments. 
 
4.3.2.4 Rottlerin and Lovastatin restrict MACC1 expression in a panel of human CRC 
cells 
Next, we analyzed the effects of these inhibitors on the MACC1 expression in different CRC 
cell lines. Upon treatment of SW620, DLD-1, Caco2 and SW480 cells with 2.5 µM Rottlerin, 
MACC1 mRNA levels were reduced to 60%, 40%, 62% and 18% of the solvent treated 
control (Fig. 4.17 A). Similarly, Lovastatin was capable of restricting MACC1 expression in 
various human CRC cells but, unlike Rottlerin, the significantly effective concentration was 
cell line dependent. In the case of SW48 cells, even 2.5 µM of Lovastatin was sufficient to 
reduce MACC1 mRNA to 40%. In the case of DLD-1 cells, 30 µM of Lovastatin was required 
to observe a 50% decrease in MACC1 mRNA levels whereas for SW620 cells, a higher 
concentration of 50 µM was required to restrict MACC1 expression to 55% (Fig. 17 B, C, D). 
We also performed a MTT assay to determine the toxicity profile of higher concentrations of 
Lovastatin on these cells. Our data (Fig. 4.15 E, F) demonstrates different sensitivity profiles 
of these CRC cell lines towards Lovastatin treatment and in all the cell lines, MACC1 
expression was inhibited at non-toxic concentrations. 
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Figure 4.17 Effect of Rottlerin and Lovastatin on MACC1 expression in various CRC cell lines. 
A) CRC cells were treated with 2.5 µM Rottlerin for 24 h. MACC1 mRNA expression was analyzed by 
qRT-PCR and results were normalized with G6PDH and expressed as percentage of solvent treated 
SW620 cells. Increasing dose of Lovastatin treatment was carried out in (B) SW48 (C) DLD-1 (D) 
SW620 cells and MACC1 mRNA was quantified using qRT-PCR. Data represent mean ± SEM from 
three independent experiments. E) HCT116 and SW48 cells were treated with increasing 
concentrations of Lovastatin for 24 h and then MTT assay was performed. F) SW620 and DLD-1 cells 
were treated with a higher concentration range of Lovastatin for 24 h and MTT was performed. 
Percentage viability of treated cells was calculated over solvent treated control cells. Data represent 
means ± SEM (n≥2). 
4.3.3 Small molecule inhibitors do not affect exogenous MACC1 expression 
To demonstrate that Rottlerin and Lovastatin are transcriptional inhibitors of MACC1, we 
hypothesized that exogenous overexpression of MACC1 governed by a promoter other than 
its own MACC1 promoter should be resistant to the inhibitory effects of our drugs. Therefore, 
HCT116 cells were transiently transfected to express CMV-promoter-driven MACC1 cDNA. 
As result, HCT116/MACC1 cells had at least 10 times increased MACC1 mRNA level 
compared to HCT116/vector cells. The MACC1 protein level too was clearly increased in 
these cells as compared to HCT116/vector cells. 
Treatment of HCT116/vector cells with 2.5 µM Rottlerin (Fig. 4.18 A) or 5 µM Lovastatin 
(Fig. 4.18 B) reduced the MACC1 mRNA level to more than 50% of the solvent-treated 
control, which was similar to the effect observed in HCT116 cells. In contrast, treatment of 
HCT116/MACC1 cells with the same concentration of Rottlerin or Lovastatin did not result in 
a significant change in the MACC1 mRNA. Similar to the effects observed at mRNA levels, 
MACC1 protein expression in the HCT116/vector cells was decreased when cells were 












Figure 4.18 Effect of Rottlerin and Lovastatin on HCT116/vector and HCT116/MACC1 cells. 
HCT116 cells were transiently transfected to express CMV-promoter-driven MACC1 cDNA 
(HCT116/MACC1) or the empty vector (HCT116/vector) as control. Cells were treated with 2.5 µM 
Rottlerin (A) or 5 µM Lovastatin (B) for 24 h and MACC1 mRNA and protein levels were analyzed by 
qRT-PCR and Western blot, respectively. Data represent means ± SEM (n>3).  
4.3.4 Small molecule inhibitors decrease cell proliferation and migration 
4.3.4.1 Rottlerin and Lovastatin inhibit cell proliferation 
One of the hallmark of cancer is enhanced proliferation rate of the cancer cells [160]. 
Therefore, for the identification of any anti-cancer drug, it is important to characterize its 
effect on proliferation. Moreover, MACC1 has been shown to be responsible in conferring 
properties contributing to metastasis, such as increased cell motility and proliferation, which 
are one of the first cellular processes that trigger metastasis formation [108]. Thus inhibition 
of MACC1 should lead to reduction in cell motility and proliferation. In order to evaluate that, 
we performed MTT assay to analyze anchorage-dependent proliferation of HCT116 cells 
upon treatment with small molecule MACC1 inhibitors. Treatment of HCT116 cells with either 
2.5 µM of Rottlerin or 5 µM Lovastatin daily resulted in a significantly reduced cell 
proliferation after 48 h (Fig. 4.19). On day 3, Lovastatin only partially inhibited proliferation of 
HCT116 cells whereas Rottlerin completely attenuated the growth of HCT116 cells. These 
results indicate that Rottlerin and Lovastatin both possess anti-proliferative abilities in vitro 
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4.3.4.2 Rottlerin and Lovastatin arrest colony formation 
Anchorage-independent growth of cells in soft agar is an important attribute of cancer cells 
representing cellular transformation, uncontrolled growth and metastatic behavior [161]. 
Anchorage-independent growth was investigated with the soft agar colony formation assay. 
Solvent-treated HCT116 cells were able to form large, clearly visible colonies within 12-14 
days. In contrast, the size and number of the colonies formed were significantly reduced 
upon Rottlerin or Lovastatin treatment. Rottlerin treatment reduced the number of colonies to 
56% of solvent control cells whereas treatment with Lovastatin reduced the number of 
colonies to 32% of solvent control cells (Fig. 4.20). Thus, to conclude, Rottlerin and 
Lovastatin possess both anchorage-dependent and anchorage-independent anti-proliferative 
abilities on HCT116 cells which might be partially explained by their specific inhibitory effect 
on MACC1 expression. 
 
4.3.4.3 Rottlerin and Lovastatin reduce cell migration 
A major phenotype imparted by MACC1 is increased migration of the CRC cells [108, 113]. 
Thus, we investigated the effects of our small molecule MACC1 inhibitors on cell motility. 
Fig. 4.19 Effect of Rottlerin 
and Lovastatin on anchorage-
dependent cell proliferation. 
HCT116 cells were treated with 
daily doses of 2.5 µM Rottlerin 
or with   5 µM Lovastatin and the 
proliferation was analyzed daily 
with MTT assay for 4 days 
consecutively. Control cells 
were treated with equivalent 
amount of DMSO. The values 
were normalized to day zero 
values. Data represent mean ± 
SEM (n>3).  
 
Fig. 4.20 Impact of Rottlerin and 
Lovastatin on anchorage indepen
d-ent cell proliferation.  
Anchorage-independent growth of 
HCT116 cells upon treatment with 
2.5 µM Rottlerin or 5 µM Lovastatin 
was analyzed by colony formation 
assay. Control cells were treated 
with equivalent amount of DMSO. 
Both small molecule inhibitors 
reduced the size and number of 
HCT116 cell colonies. Colonies were 
counted under light microscope on 
day 12-14. Data represent mean ± 
SEM (n>3).  
 






Migration was calculated at two different time points of 24 h and 48 h. The number of 
migrated cells over a time point of 48 h was more than two-fold as compared with 24 h time 
point. Further, the number of migrated cells upon treatment with 2.5 µM Rottlerin or 5 µM 
Lovastatin for 24 h was reduced up to 24% and 20% of solvent-treated cells, respectively, 
and was further reduced to 10% and 8.6%, when treated for 48 h (Fig. 4.21 A, B). As shown 
in figure 4.19, Rottlerin and Lovastatin at 2.5 and 5 µM respectively have no effect on 
proliferation at 24 h, suggesting that the effect on migration at this time point is mostly 
independent of the proliferation. On the other hand, proliferation starts to decrease 
significantly at 48 h post treatment with Rottlerin and 
Lovastatin, suggesting that the effect we observe on migration at 48 h is probably a 
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Fig. 4.21 Effect of Rottlerin and Lovastatin on cell migration. A) HCT116 cells were treated with 
2.5 µM Rottlerin or 5 µM Lovastatin for 24 h and 48 h and cell migration was measured with the 
Boyden chamber assay. Migrated cells were fixed with 100% methanol and stained with DAPI. 
Control cells were treated with equivalent amount of DMSO. The representative images are shown. B) 
The migrated cells from five fields were counted manually under a fluorescent microscope and 
represented in the bar graph. Data represent means ± SEM (n=2). C) Directed migration of Rottlerin, 
Lovastatin or solvent-treated HCT116 cells was analyzed by wound healing assay. Microphotographs 
were taken 24 h and 48 h post treatment with 10x magnification. Assay was performed three times; 
one representative picture is presented here. 
 
Similar effects were observed for directed-migration of HCT116 cells analyzed by wound 
healing assay as previously described [162]. When cells were treated only with solvent, 
HCT116 cells were able to infiltrate the wound and close it completely within 48 h. Treatment 
of HCT116 cells with 2.5 µM Rottlerin or 5 µM Lovastatin inhibited the wound closure as 
compared to the solvent treated cells (Fig. 4.21 C).  
In summary, it can be concluded that both small molecule inhibitors are able to decrease 
MACC1 expression and, thereby, arrest primary attributes associated with this gene, i.e. 
migration and proliferation, making them suitable candidates as metastasis inhibitors.   
 
4.3.5 Small molecule inhibitors interfere with the MACC1 transcriptional regulation 
4.3.5.1 Rottlerin and Lovastatin inhibit Sp1 expression 
We have demonstrated in our result section 4.1 that AP-1 and Sp1 play an important role in 
governing MACC1 transcriptional regulation. Thus, after validating MACC1 inhibitors in vitro 
we were interested in studying the mechanism by which our small molecule inhibitors restrict 
MACC1 transcriptional regulation. With the already acquired knowledge of the roles that 
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 AP-1 and Sp1 play in transcription of the MACC1 gene, we would like to assess the effect of 
our inhibitors on these transcription factors regulating MACC1. Therefore, we first started by 
analyzing their effect on Sp1 expression. Treatment of HCT116 cells with Rottlerin and 
Lovastatin significantly inhibited the Sp1 mRNA levels by 57% and 23%, respectively, as 
compared with the solvent treated cells. These effects were more prominent as reflected in 
the Sp1 protein levels upon drug treatment as demonstrated by Western blotting. Thus, the 
inhibition of MACC1 by these inhibitors could be partially explained via decrease in Sp1 
levels, thereby reducing transcription of the MACC1 gene. 
 
 
                                                
 
 
Figure 4.22 Effect of Rottlerin and Lovastatin on Sp1 expression. HCT116 cells were treated with 
2.5 µM Rottlerin or 5 µM Lovastatin for 24 h and Sp1 mRNA and protein level were analyzed by qRT-
PCR and Western blot, respectively. Control cells were treated with equivalent amount of DMSO. 
Black Line represents grouping of data after removal of an extra control lane. Data represent mean ± 
SEM (n=3).  
4.3.5.2 Small molecule inhibitors hinder the binding of c-Jun with the MACC1 promoter 
Surprisingly, treatment of HCT116 cells with Rottlerin and Lovastatin showed increased 
levels of c-Jun expression both at mRNA and protein levels (Fig. 4.23 A). Therefore, we 
hypothesized that these small molecule inhibitors may act within the nucleus and obstruct the 
binding of AP-1 with the MACC1 promoter. This hypothesis was tested by EMSA, using 
biotinylated oligonucleotides encompassing AP-1 binding site of the MACC1 promoter as 
described earlier. In solvent-treated HCT116 cells, signal shifts were observed which were 
caused by binding of c-Jun to the oligonucleotides as consistent with our previous findings 
(Fig. 4.4). Exposure of HCT116 cells to Rottlerin and Lovastatin interrupted the binding of 
AP-1 with the MACC1 promoter (Fig. 4.23 B). The specificity of the AP-1/MACC1 promoter 
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complex was verified by the addition of c-Jun antibody leading to disappearance of the shift 
(Fig. 4.23 C).  
Similar results were found with ChIP assay (Fig. 4.23 D). Solvent-treated cell extracts 
showed two fold more enrichment of MACC1 promoter sequence after c-Jun 
immunoprecipitation as compared with Rottlerin or Lovastatin treated cell extracts. These 
results indicate that small molecule inhibitors inhibit AP-1/MACC1 promoter binding and 




             
 
                    
                    













Figure 4.23 Effect of Rottlerin and Lovastatin on the binding of c-Jun to the MACC1 promoter. 
A) HCT116 cells were treated with 2.5 µM Rottlerin or 5 µM Lovastatin for 24 h and c-Jun mRNA and 
protein level were analyzed by qRT-PCR and Western blot, respectively. Black line represents 
grouping of data after removal of an extra control lane. B) EMSA was performed with equal amounts of 
nuclear extracts isolated from the HCT116 solvent-control and treated cells followed by incubation with 
5‟ biotin labeled MACC1 promoter oligonucleotides flanking binding sites specific for AP-1. A reaction 
with 100x molar excess of unlabeled competitor sequence was also carried out indicating the 
specificity of the protein-DNA complexes. The reactions were analyzed by polyacrylamide gel 
electrophoresis. C) For supershift analysis, the nuclear extracts were incubated with biotin labeled 
oligonucleotides along with antibodies for c-Jun. Representative figure from two independent 
experiments is depicted. D) Equal amounts of HCT116 solvent-control and treated cells chromatin was 
immunoprecipitated with antibodies for c-Jun and was quantified by qRT-PCR, using primers for the 
MACC1 promoter. The results were plotted as percentage of input. Data represent mean ± SEM (n=3) 
 
4.3.6 Rottlerin inhibits tumor growth in CRC xenograft mice 
In vitro studies demonstrated a strong potential of Rottlerin as an inhibitor of MACC1 and 
justified the need to access its anti-proliferative and anti-migratory abilities in vivo. Thus, we 
analyzed the anti-cancerous and anti-metastatic effects of this small molecule inhibitor using 
xenografted mice. Intrasplenic transplantation of HCT116 cells into SCID mice was used as a 
model to analyze the effect of Rottlerin on primary tumor and liver metastases [108].  
4.3.6.1 Rottlerin application in vivo caused no toxic side effects 
For dose-finding experiments in human CRC xenografted mice, NOD-SCID mice were 
intrasplenically injected with HCT116/LUC cells and were intraperitoneally treated with daily 
doses of 1 mg/kg, 5 mg/kg or 10 mg/kg of Rottlerin or the respective amount of solvent, in 
cooperation with PD Dr. Iduna Fichtner (MDC). Body weight was measured as a first 
indicator for toxic side effects [163]. Body weight of the mice treated with the highest 
concentration of 10 mg/kg Rottlerin did not differ from the solvent-treated control (Fig. 4.24 
A). Thus concentration of 8 mg/kg was selected for further experiments. 
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Fig. 4.24 Evaluation of Minimal tolerable dose (MTD) of Rottlerin for in vivo administration in 
mice. Indicated concentrations of Rottlerin were injected daily intraperitoneally into NOD-SCID mice 
bearing an intrasplenal HCT116/LUC tumor for seven days. Body weight was determined as an 
indicator for toxic side effects. Data represent mean ± SD (2 animals/group) (B) No difference in 
weight loss was observed between solvent or Rottlerin (8 mg/Kg)-treated mice, over a period of 27 
days. Data represent means ± SD (4-5 animals/group)  
4.3.6.2 Rottlerin restricted MACC1 expression and tumor growth in vivo  
Bioluminescence imaging presents a non-invasive tool to assess tumor growth and 
development over time and is a state of the art technique in cancer research [164]. To track 
the growth of the human CRC cells in the immune-deficient mice, HCT116/LUC cells were 
used. These cells express MACC1 endogenously along with a CMV-promoter controlled 
firefly luciferase gene. This enzyme allows the oxidation of D-Luciferin, which leads to the 
emission of light. To monitor the effect of Rottlerin on tumor growth in vivo, HCT116/LUC 
cells were intrasplenically injected into NOD-SCID mice and the animals were treated daily 
with 8 mg/kg Rottlerin or the respective amount of solvent. A lateral signal became visible on 
day 5 post-transplantation in solvent- and Rottlerin-treated mice, which was assigned to the 
spleen (Fig. 4.25 A). This spleen tumor signal increased over time in the solvent-treated 
group whereas in the case of Rottlerin-treated mice, the growth was much slower starting 
from the beginning and the difference became clearly visible on day 19. Furthermore, on day 
27, when the signal crossed the threshold value in the intensity bar in solvent-treated group, 
the Rottlerin treated mice still had signals within the range. However, solvent-treated control 
mice upon ventral imaging revealed almost no signal in the liver region on day 27 indicating 
that liver metastases had not been formed in these tumors. The experiment was terminated 
on this day and the animals were sacrificed. On isolating the organs, we clearly observed 
that in the Rottlerin treated group, the spleen tumor was much smaller as compared to 
solvent treated (Fig. 4.25 B). Moreover, the reduction in spleen weight (Fig. 4.25 C) in the 
Rottlerin-treated group as compared with solvent control group further strengthens our 
B 




finding. However, livers from the control group were mostly clean with no or only tiny tumor 
outgrowths (Fig. 4.25 B). 
In order to ascertain that the drug is inhibiting MACC1 levels in vivo, we isolated RNA from 
spleen and performed qRT-PCR. Our PCR results indicate that Rottlerin is strongly inhibiting 
MACC1 expression (Fig. 4.25 D) thereby restricting the primary tumor growth. 
Thus, to summarize, Rottlerin at the dose of 8 mg/kg inhibited MACC1 levels and restricted 
the tumor growth in vivo. However, its effect on liver metastasis cannot be speculated from 
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Fig. 4.25 Effect of Rottlerin in CRC xenografted mice as monitored by non-invasive 
bioluminescence imaging. NOD-SCID mice were intrasplenically transplanted with HCT116/LUC 
cells and mice were treated intraperitoneally with 8 mg/kg Rottlerin every day. Bioluminescence was 
measured by intraperitoneal application of 150 mg/kg D-Luciferin and sequence exposure of 1 min for 
10 times in the NightOWL LB 981 system. A) The lateral signal from the spleen tumor as monitored via 
imaging over time in solvent- and Rottlerin-treated mice. B) Ex vivo imaging of isolated organs 
confirmed the signals seen above. C) Total body weight and spleen weight was measured on day 27 
after xenografting and spleen weight in percentage of body weight was calculated. D) On day 27, the 
animals were sacrificed and the spleens were shock frozen. RNA was isolated from this frozen spleen 












































Over the last few years, a substantial increase in five-year survival rate of the CRC patients 
has been observed, but this increase was primarily restricted for patients with localized 
cancer and no progress was observed for patients with advanced disease [1]. Understanding 
of the heterogeneous nature of cancer has brought the emergence of a new era of 
personalized medicine, embracing a more stratified approach to cancer management. The 
success of personalized therapy demands a clear knowledge of the molecular underpinnings 
of the disease defining the clinical characteristics of different patient sub-populations with 
different outcomes in relation to a given treatment.  
Almost five years ago, MACC1 was identified as a prognostic biomarker and as an indicator 
of pathogenic process leading to CRC metastasis [2]. Since then, various follow-up studies 
had emphasized the importance of MACC1 in progression of CRC and had also provided 
hints towards its role as predictive marker [3-10]. However, the characteristics of the MACC1 
promoter, as well as the mechanisms governing MACC1 gene regulation remained largely 
unknown. Of note, targeting MACC1 with shRNA in xenografted mice demonstrated a 
reduction in the rate of tumor progression and metastasis formation suggesting that inhibition 
of MACC1 provides a promising therapeutic strategy for restricting CRC progression and 
metastasis intervention [132]. Though, the pharmacological targeting of MACC1 with small 
molecule chemical compounds and their impact on CRC progression has not been 
addressed so far. 
Therefore, this study has addressed MACC1 gene regulation through identification of the 
MACC1 promoter followed by studying the transcription factors governing transcription of the 
MACC1 gene. This knowledge was then translated to identify and investigate two novel 
MACC1 transcriptional inhibitors in CRC cells leading to reduced MACC1 expression and 
thus, consequently reduced proliferation and migration in vitro and tumor progression in vivo. 
Our study broadens the existing knowledge underlying the molecular mechanism behind 
MACC1-induced-tumor progression and metastasis formation and further strengthens its role 










5.1 Transcriptional regulation of the MACC1 gene 
5.1.1 Identification and relevance of the MACC1 core promoter region 
Analysis of the 5‟ flanking region upstream of the TSS in the MACC1 gene, revealed that the 
genomic fragment spanning nucleotides -992 to -18 bp contains the promoter region for the 
MACC1 gene, which can be further extended up to -1992 bp as both MACC1 long range 
promoter constructs (MACC1p-992 and MACC1p-1992) were able to drive transcription. 
However, luciferase assays performed with 5‟ serially truncated MACC1p-992 constructs 
revealed a minimal essential core promoter region spanning between the nucleotides from -
426 to -18 bp. This core promoter region possessed a comparable promoter activity as the 
long range promoter itself indicating that it contains all information required to drive 
transcription of MACC1. Of note, we found high degree of similarity in this core promoter 
region between human and mouse MACC1 promoter sequence. This core promoter region 
might not be only responsible for initiation of transcription but it might play a role in tethering 
together all the elements that are required for the basal activation of the MACC1 gene. 
These are often called as regulatory promoters. However, the long range promoter might be 
responsible for tissue specific expression or might play a role in protecting the gene from the 
positive and negative influences exerted by the chromatin at the site of integration very often 
termed as positional effect [165]. In addition, distant genomic elements namely enhancers, 
repressors or insulators can be located upstream, within introns, or downstream of the 
regulatory promoter [166]. Furthermore, multiple alternative promoters can dictate the 
strategy of gene expression as it is the case of the well characterized human Bcl2 gene 
which possess a Sp1 binding site and no TATA box and demonstrate multiple sites of 
transcription initiation. Nevertheless, the aim of our study was to investigate the regulatory 
promoter of the MACC1 gene. Distant genomic elements and presence of alternative 
promoters for the MACC1 gene needs to be investigated in the future. 
5.1.2 Exploration of the transcriptional regulatory machinery of the MACC1 gene 
In silico and in vitro studies of the core promoter region revealed the presence of potential 
binding sites for various transcription factors including AP-1, Sp1 and C/EBPs. AP-1 
expression and activity is shown to be altered in many cancers, including CRC [167]. The 
fact that AP-1 has increased activity in cancer cells and is often associated with their 
transformed phenotype suggests that it may be fundamental to the process of oncogenesis 
[168-170]. We propose that MACC1 regulation via AP-1 imparts another dimension to AP-1 
as a target for cancer therapy. 




There is also emerging evidence that Sp1 protein expression may be a critical factor in tumor 
development, growth and metastasis [156]. Sp1 protein is highly expressed in the nuclei of 
gastric, pancreatic, breast, and thyroid tumors compared to their normal tissues [152, 171, 
172]. Moreover a study showed that the survival of patients with high Sp1 expression was 
significantly decreased compared to patients with weak to non-detectable Sp1 expression 
[156]. There have also been studies showing that AP-1 and Sp1 together regulate 
transcriptional activation of various human genes encoding leukocyte integrin CD11c [173], 
Involucrin [174], Loricrin [175], and the metastasis gene VIL2 (Ezrin) [176]. Furthermore, 
C/EBPs are also overexpressed in colorectal tumors [177-179]. Their role in regulating gene 
expression via regulating AP-1 has also been demonstrated in several different cell models 
[180-182]. Specific involvement of AP-1, Sp1 and C/EBP in transcription of the genes 
involved in proliferation and metastasis aroused our interest to study their role in regulating 
MACC1. In order to validate the functional relevance of the binding sites for these 
transcription factors on the MACC1 promoter, we performed site directed mutagenesis 
studies. The results demonstrated that AP-1, Sp1 and C/EBP binding sites contribute to the 
transcriptional activity of the MACC1 promoter. EMSA and ChIP experiments further 
confirmed the physical association of these elements with the MACC1 promoter.  
Taken together, these three transcription factors bind to the MACC1 promoter and might 
cooperatively regulate MACC1 expression. 
5.1.3 Regulation of MACC1 expression and MACC1- associated motility by AP-1 and 
Sp1 
RNAi strategy using target-specific predesigned siRNA for knocking down the transcription 
factors regulating MACC1 assured their effect on MACC1 expression levels. Chemical 
inhibitors for these transcription factors could be used also but the limitation for specifically 
targeting these transcription factors would have still prevailed. It remains possible that these 
transcription factors affect the expression of many additional genes or transcription factors 
already implicated in migration and metastasis. Consequently, the decreases in MACC1 
expression that follow the AP-1, Sp1 or C/EBP silencing might be direct or indirect through 
regulation of other transcription factors. For C/EBPs, it is known that either post-translational 
modification or alternative translation initiation result in diverse isoforms with opposing 
physiological roles thereby forming a C/EBP interactome which determines cell fate. 
Consequently, the role of C/EBPs in the regulation of MACC1 and MACC1-induced 
functional phenotype might depend on these epigenetic changes regulating C/EBP itself. 
Thus, we then focused on AP-1 and Sp1 and demonstrated that siRNA for these 




transcription factors induced low migratory abilities in CRC cells. The rescue experiment 
carried out by overexpressing MACC1 ectopically further convinced us that the low migratory 
abilities observed upon knocking down c-Jun and Sp1 are MACC1-specific. Therefore, AP-1 
and Sp1 regulate MACC1 expression and MACC1-associated cell motility. 
5.1.4 Expression analysis of c-Jun and Sp1 in patients with variable levels of MACC1 
The association of AP-1 and Sp1 with MACC1 was then confirmed in clinical specimens. We 
found a strong positive correlation of MACC1 expression with c-Jun and Sp1 expression in 
colorectal tumors. Our findings further reflected the interdependence of the AP-1 and Sp1 
with MACC1 levels linked to development of distant metastases. Patients with high MACC1 
expression in their primary tumors showed high c-Jun as well as high Sp1 levels. 
Remarkably, high levels of AP-1 as well as of Sp1 were also found in those tumors that later 
on developed distant metachronous-metastases. In the future, the study on a larger sample 
size might further emphasize the correlation of MACC1 with the two transcription factors and 
might also be able to clarify whether MACC1 along with c-Jun or Sp-1 increases the 
prognostic power as compared to MACC1 alone.  
5.1.5 Relevance of GIPC1 in regulating MACC1 
GIPC1 family constitutes the PDZ domain bearing members, GIPC1, GIPC2 and GIPC3. 
GIPC1 is a scaffold protein involved in trafficking of various trans-membrane proteins, 
signaling and recycling of receptor tyrosine kinases (RTKs), G protein-coupled receptors 
(GPCRs), integrin and thus regulate various cellular processes such as proliferation, planar 
cell polarity, cytokinesis and migration. One of the major pathologies associated with the 
GIPC1 is cancer. GIPC1 was found to be overexpressed in breast, ovarian, colorectal, 
gastric and pancreatic cancers [183-187]. A study reported that GIPC1 is required for 
pancreatic tumor growth in nude and SCID mice via reduction in the expression of insulin-like 
growth factor receptor I (IGF-1R) [188]. Moreover, GIPC1 knock down gene signature was 
correlated with a number of breast and ovarian cancer phenotypes and clinical outcomes, 
including patient survival as investigated using publically available breast and ovarian cancer 
microarray datasets [183]. Considering the promising role of GIPC1 in oncogenic 
transformation, we hypothesized the connection between MACC1 and GIPC1. Stable 
knockdown of GIPC1 in a high MACC1 expressing CRC cell line resulted in a decrease in 
the MACC1 expression. Interestingly, the decrease in MACC1 levels was due to a decrease 
in the MACC1 promoter activity in GIPC1 knockdown cells compared with control cells. This 
indicated that GIPC1 governs a part of the MACC1 promoter activity. Thus, we carried out 




ChIP and EMSA experiments to depict the physical interaction of GIPC1 with the MACC1 
promoter, and the results suggested that, indeed, GIPC1 binds to the MACC1 promoter and 
regulates its activity. This was the first study elucidating the role of GIPC1 as a transcription 
factor. Additionally, we demonstrated that GIPC1 might bind to the first 133 bp upstream of 
the TSS, but it remains unclear whether GIPC1 act as an accessory molecule to mediate 
transcription of the MACC1 gene or directly binds to the MACC1 promoter sequences and 
plays an essential role in oncogenic transformation mediated by MACC1. 
5.1.6 Summary and scope: MACC1 promoter study 
Our present work led to the identification of the MACC1 regulatory promoter and transcription 
factors which bind to it and contribute to MACC1-associated metastasis in CRC (Fig. 5.1). 
Until now, the majority of the studies on the biomarker MACC1 were associated with the 
clinical implication of this gene. Our results contribute to the understanding of the molecular 
interactions of AP-1, Sp1, C/EBPs and GIPC1 with the gene promoter. Oncogenic 
transcription factors such as AP-1 and Sp1 are particularly promising therapeutic targets 
since they often have increased expression and activity in a variety of cancers. Associated 
with this is the fact that they mediate signals coming from multiple different pathways, hence 
inhibiting their function will likely to interfere with the function of numerous signaling 
molecules which could have favorable or unfavorable outcome on the cancer patient. A 
relevant approach could be the identification of a  drug which rather than completely 
inhibiting c-Jun or Sp1 expression, impairs its binding with the specific gene promoter, in our 
case, MACC1, and thus arrest oncogenic transformation. It has been shown that different 
C/EBP isoforms might have different roles in tumor formation and progression, C/EBP-α 
seems to be a general tumor suppressor in both hematopoietic and non-hematopoietic cell 
types whereas C/EBP-β might both inhibit and promote cell cycle progression, depending on 
the cellular context and C/EBP-β forms present [177]. Therefore, the role of C/EBPs in the 
context of MACC1 regulation warrants further elucidation. Lastly, therapeutic implication of 
GIPC1 in cancer has already been speculated [183] and our study strengthens its promise as 
a new target for cancer. 
Thus, the knowledge acquired from our present study might provide a rationale for the 
development of various intervention strategies targeting MACC1 expression, thereby 
translating this new knowledge into clinical applications. 





Fig. 5.1 Regulation of the MACC1 promoter. Schematic representation of the MACC1 
promoter and its regulation by GIPC1, Sp1, C/EBP and AP-1 transcription factors. 
5.2 MACC1 as a new target for advanced colorectal cancer therapy 
Cancer biomarkers bear multi-faceted aspects in cancer intervention. They can be used for 
cancer diagnosis, risk and prognosis assessments and for predicting effectiveness of the 
particular therapy. In addition, some biomarkers can be used as targets for cancer therapy. 
As stated by Zhiyuan Shen, biomarkers can be of two types, one are simply “messengers”, 
and that do not directly contribute to cancer growth and hence cannot be targeted for 
therapies. While the second class of biomarkers are called as “driver” or “conspirator” 
biomarkers that directly contribute to tumor growth and hence can be exploited for their 
efficacy as a therapeutic target [189]. As mentioned above, MACC1 has been established by 
various studies as a prognostic biomarker for colorectal cancer metastasis [108-
111,114,115,117]. It has also been demonstrated in these studies along with many other 
[117, 124, 125, 127, 129, 132, 190, 191] that MACC1 levels can act as a decisive driver for 
the switch between adenoma to carcinoma and thus initiate cancer progression and 
ultimately metastasis. Interestingly, MACC1 was also found to be up-regulated in intestinal 
stem cell populations with Lgr5-GFP high expression indicating that MACC1 in the stem cell 
population could be one of the potential reasons for tumor relapse [134]. Therefore, in our 
study, we hypothesized the potential of MACC1 for targeted therapy and thus aimed to target 
MACC1 to intervene in CRC progression. 
5.2.1 HTS implicated in identification of novel small molecule MACC1 inhibitors 
As discussed earlier, patients with elevated levels of MACC1 in their primary tumors showed 
higher risk of metastasis, cancer recurrence and low metastasis free survival. In addition, 
xenografted mice treated with shRNA MACC1 showed reduction in primary tumor and liver 
metastasis [132]. RNA interference as therapeutics modality is still under clinical trial and has 
not been adopted because of its off target effects, ability to trigger type I interferon 
responses, competition with cellular RNAi components and most importantly, for the 
challenges it impose on the effective delivery in vivo. As an alternative, we aimed at the 
investigation of chemical compounds that can inhibit MACC1 and MACC1-induced 




oncogenic transformation and thereby, reduce the risk of patients to progress towards 
advanced stages of CRC.  
Inhibiting the expression of a gene could be achieved via several mechanisms. We could 
design inhibitors which bind reversibly or irreversibly to the protein of interest and blocks its 
function. Others might be epigenetic inhibitors, transcriptional or post translational inhibitors. 
Structural insight and the protein structure of the MACC1 gene are still unknown. Thus, we 
designed a strategy to investigate chemical compounds that can inhibit transcription of the 
MACC1 gene by manipulating its promoter activity, which was only possible because of our 
previous identification of the MACC1 promoter.  
In order to identify chemical drugs targeting MACC1 transcription, we performed HTS with a 
Chembionet library of more than 30,000 compounds using HCT116 cells stably transfected 
with MACC1 promoter-luciferase constructs. Out of 30,000 compounds, 97 compounds, 
which included seven pharmacologically active and 90 novel compounds, emerged as 
potential candidates which specifically inhibited MACC1 promoter activity. We selected 
pharmacologically active compounds which inhibited MACC1 promoter activity because of 
their better chances in terms of clinical development. This led us to the identification of two 
MACC1 inhibitors namely Rottlerin and Mevastatin. 
5.2.1.1 Rottlerin and known biological activities 
Rottlerin is a plant derived compound obtained from the reddish brown powder covering the 
berries of the Mallotus philippinensis (also known as Kamla tree). This tree is usually found in 
the tropical regions of India, Philippines, Southeast Asia and Australia. It is a spectacular 
plant with different parts of it possessing different biological activities and is used as 
traditional medicines. According to Ayurveda, the leaves of this tree are a good appetizer. Its 
fruit bears heating, purgative, anthelmintic, vulnerary, detergent, carminative, alexiteric 
properties. Phloroglucinol derivatives obtained from the fruit of this plant possess anti-allergic 
properties [192] whereas seed extract showed antifertility actions [193]. The reddish brown 
powder (Rottlerin) is locally used for coloring textile and is used for centuries as an old 
remedy against tape worm infection because of its laxative effect, indicating its safety profile 
as a drug [194]. 
Rottlerin is also known as Mallotoxin and its molecular formula is C30H28O8 with a molecular 
weight of 516.5 g/mol. IUPAC name for Rottlerin is (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-
methylphenyl) methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one. It 
emerged as a compound of commercial importance following the study reporting it as a 
selective PKCδ inhibitor [195]. However there is an open debate on the selectivity of 




Rottlerin. Rottlerin was demonstrated to uncouple mitochondrial respiration from oxidative 
phosphorylation, reducing cellular ATP levels and thereby, it non-specifically inhibits PKCδ 
kinase activity in cultured cells [196]. Nonetheless, many studies have continued to use and 
show consistent and convincing results using Rottlerin to inhibit PKCδ signaling [197, 198].                  
         
Figure 5.2: Fruit of Kamala tree and Rottlerin structure. (Adapted from biotik.org/India) 
Apart from its anthelmintic and laxative effect against tapeworm, it has also  shown potential 
as potassium channel (BKCa++) opener, thus reported to have cardio-protective effects after 
ischemic-reperfusion injury [199]. Rottlerin, through inhibition of PKCδ is reported to have a 
neuro-protective effect in an animal model of Parkinson's disease [200]. Additionally, it also 
possess anti-inflammatory properties [201] and very recently it was reported as a small 
molecule therapeutics for asthma [202].  
Rottlerin exhibits diverse effects against various cancer cells. It can induce apoptosis or 
autophagy through different mechanisms in different cancer models [203-208]. Rottlerin is 
also shown to reduce cell motility and invasiveness via decreasing levels of integrin β1, FAK, 
paxillin, Rac-1, Rho GTPases [209-211] and MMP9 [212, 213]. Still, the mechanisms 
underlying the Rottlerin anti-cancer properties are relatively poorly understood and its role as 
an anti-cancer agent is not established. In this study, we explored a new target of Rottlerin 
and further established its potential as a therapeutic drug against CRC. 
5.2.1.2 Statins and known biological activities 
The second potential MACC1 transcriptional inhibitor that emerged from the HTS was 
Mevastatin. It belongs to the class of drugs “Statins” which reduce cholesterol levels by 
inhibiting the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. This inhibits 
the rate limiting step in the mevalonate pathway of cholesterol synthesis and is thus a useful 
drug to treat hypercholesterolemia [214]. Mevastatin (also known as Compactin) was the first 




statin, isolated from Penicillium citrinum, which was found to have powerful inhibitory effect 
on HMG-CoA reductase [215-217]. Unfortunately, Mevastatin never came into the market 
due to its severe side effects and toxicity in dogs. However, in 1978 a new statin, Lovastatin, 
isolated from Aspergilus terreus was identified by Alfred Alberts and colleagues which was 
found to be effective in reducing blood cholesterol [218]. In 1987, it was approved for sale by 
the FDA as the first cholesterol-lowering drug. Subsequently, several other HMG-CoA 
reductase inhibitors like Simvastatin, Pravastatin, Fluvastatin, Atorvastatin, Cerivastatin and 
Rosuvastatin came into the market. 
  
Apart from the lipid-lowering potential of Statins, several studies have speculated its effect on 
tumor development through multiple mechanisms (Fig. 5.4). Remarkably, in the molecular 
Epidemiology of Colorectal Cancer study, including 1953 patients with CRC and 2015 
controls, statin usage was associated with a 47% decrease in the relative risk of CRC (odds 
ratio, 0.50) [219]. However, the molecular mechanisms of the effects of statins against 
cancer are not completely elucidated. In our study, we investigated the role of Lovastatin in 
CRC progression mediated by MACC1 in order to strengthen its therapeutic value in 
oncology. 
Figure 5.3: Lovastatin structure and its commercial 
manufacturing by Merck. (Adapted from toxnet.nlm.nih.gov) 
 





Figure 5.4: Potential mechanism of action of Lovastatin in Cancer. Modified after Kaushal et al. 
[220]. 
5.2.2 MACC1 inhibitors restrict MACC1 expression and MACC1 associated biological 
properties 
Based on our HTS, we identified the first small molecule MACC1 inhibitors known so far, 
Rottlerin and Lovastatin. Both the compounds inhibited MACC1 promoter activity indicating 
that they exert their effect via impairing MACC1 transcription. Consequently, in this study it 
was shown that both small molecule inhibitors reduced MACC1 mRNA and protein 
expression in CRC cells but the effects were dependent on drug concentration, time of 
treatment and the cell line used. This is the first study demonstrating the effect of Rottlerin 
and Lovastatin on MACC1. In contrast to the remarkable drop in MACC1 mRNA levels 
observed upon treatment with Rottlerin after 18 h, the maximum inhibition of MACC1 mRNA 
by single dose of Lovastatin was observed at 36 h. However, at the protein level, we 
observed a time-dependent decrease in MACC1 starting from 24 h onwards upon treatment 
with either of the drugs, probably because of different in vivo half-lives of the MACC1 protein 
like many other proteins [221]. Consistent with our findings, both small molecule inhibitors did 
not affect exogenously overexpressed MACC1 levels controlled by a CMV promoter. 
Therefore, the effects on MACC1 expression are specific for endogenous MACC1 regulated 
by the MACC1 promoter. 




Further, treatment of CRC cells with Rottlerin or Lovastatin inhibited anchorage-dependent 
and independent cell proliferation. Knock-down of MACC1 levels using RNA interference 
strategy was shown to restrict cell proliferation and tumorigenicity in nasopharyngeal, 
cervical, osteosarcoma, glioblastoma and gastric cancer cell lines [108, 128, 129, 222-224]. 
These studies have also shown that knock-down of MACC1 resulted in G0/G1 arrest and 
inhibition of Akt signaling. A decreased MACC1 expression upon treatment of CRC cells with 
Rottlerin and Lovastatin, thus, showed decrease of cell proliferation and colony formation. 
These effects could be an outcome of reduced MACC1 levels but the possibility of an 
independent mechanism contributing to decreased proliferation along with low MACC1 levels 
still prevails.  
Additionally, MACC1 is a major regulator of cell motility [108, 109, 114, 117, 126-128, 130, 
135, 190, 223]. Knock-down of MACC1 using RNAi experiments restricted cell migration and 
invasion. Though, a molecular mechanism elucidating the role of MACC1 in metastasis 
remains unclear. CRC cells upon treatment with Rottlerin or Lovastatin inhibited cell 
migration and wound healing. This effect could be partially because of suppression of 
MACC1 expression. However, there have been studies suggesting anti-migratory effects of 
Rottlerin [209-211, 225], mostly by destabilization of the focal adhesion complex or PKC-δ 
inhibition followed by reduced E-cadherin expression. These effects need to be verified 
further and it could be possible that these effects are a consequence of reduced MACC1, 
thereby contributing to low migratory ability induced by Rottlerin. Similarly for Lovastatin, it 
has been shown that it reduces migration in colon cancer cells though the mechanism has 
not been described [226]. Simvastatin, a Lovastatin analogue, was found to inhibit migration 
in the monocytic cell line THP-1 by decreasing the levels of MMP9 or by inhibiting the 
production of chemokines [227, 228]. Remarkably, the role of MACC1 in altering levels of 
MMP9 [127] and in inflammation [147, 148, 229, 230] has already been speculated. 
Therefore, the decrease in migration via decrease in MMP9 or inhibition of chemokines might 
be correlated with decrease in MACC1 levels. A detailed study on the mechanism by which 
MACC1 alters the cell motility and reduce metastatic potential, needs to be investigated in 
the future.  
5.2.3 Both inhibitors interfere with AP-1 and Sp1 mediated transcription of the MACC1 
gene 
In the first part of our study, we showed that AP-1 and Sp1 play an important role in 
regulating MACC1 transcription. On identifying Rottlerin and Lovastatin as MACC1 
transcriptional inhibitors, we demonstrated the mechanism by which they inhibit MACC1 




transcription mediated by AP-1 and Sp1. Treatment of HCT116 cells with both small 
molecules reduced Sp1 expression which then affected its binding with the MACC1 promoter 
consequently leading to decreased MACC1 transcription. The role of Rottlerin in inhibiting 
Sp1 was also previously described in cardiac myofibroblast cells [231]. However, the effect of 
Lovastatin on Sp1 levels has not been described so far. In this study, analysis of Sp1 mRNA 
levels revealed that Rottlerin inhibits Sp1 transcription, whereas for Lovastatin, a very small 
effect was seen at mRNA level but a clear effect was observed at protein level. The 
difference in the levels of Sp1 mRNA and protein upon treatment with the small molecule 
inhibitors could be accounted by extensive post translational modifications of Sp1 that 
regulate Sp1 protein level [232]. 
In contrast to their effects on Sp1, Rottlerin and Lovastatin treatment increases the level of c-
Jun mRNA and protein. However, we demonstrated that c-Jun regulates MACC1 expression 
and knock-down of c-Jun using siRNA inhibits MACC1 expression. Therefore, this increase 
in expression levels of c-Jun by MACC1 inhibitors was surprising and suggested that in CRC 
cells, Rottlerin and Lovastatin control AP-1 mediated MACC1 promoter regulation via a 
different mechanism. AP-1 is a well-known transcription factor and it translocate into the 
nucleus and binds to promoters of several genes to activate gene transcription [233]. Using 
ChIP and EMSA assay, we demonstrated that despite of increased levels of AP-1 upon 
treatment with Rottlerin and Lovastatin, MACC1 transcription was impaired in CRC cells. 
Analysis of c-Jun/MACC1 promoter binding revealed that both the small molecule inhibitors 
disrupt the binding of c-Jun to the MACC1 promoter. This could be either due to inactivation 
of the DNA binding domain of c-Jun or via inhibition of accessory proteins which are required 
by Ap-1 to bind to the MACC1 promoter or could be by inhibition of phosphorylation of c-Jun 
rendering the c-Jun protein ineffective for binding to the MACC1 promoter. However, within 
the scope of this study it was demonstrated that both the small molecule inhibitors interfere 
with the transcription factors binding to the MACC1 promoter, thereby impairing MACC1 
transcription in CRC cells. 
5.3 Rottlerin as a novel treatment option for advanced CRC patients 
5.3.1 Rottlerin as a promising MACC1 inhibitor in vivo 
In this study, both small molecule inhibitors restricted MACC1 expression in vitro and show 
promises as potential MACC1 inhibitors to halt carcinogenesis.  
HMG-CoA reductase inhibitors, also called Statins, possess diverse effects beyond their 
cholesterol-lowering properties and risk of myopathy. Though preclinical data points towards 




effectiveness of Statins in demonstrating antineoplastic effects in a variety of tumors, clinical 
studies have provided conflicting data in the role of statins in prevention or as adjuvant 
therapy in CRC cancer [234]. There have been lots of speculation and controversy regarding 
the alarming increase in breast cancer incidence with intake of Statins [235, 236]. However, 
close inspection of Statin trials is warranted to reveal a specific population at risk with Statin 
treatment.  Further research is needed to assess more precisely the effect and safety profile 
of statins, or as combination agents with adjuvant or neo-adjuvant chemotherapy. In contrast, 
Rottlerin in vivo potency remains nearly unknown but its promising anti-cancerous effects 
prospects are greatly anticipated. Thus, we decided to carry out a first in vivo study with 
Rottlerin to assess its role as a MACC1 inhibitor and thus as an inhibitor of CRC progression 
and provide preclinical data for the justification of clinical studies in humans as a CRC 
treating approach. 
 
5.3.2 Bioluminescence imaging of xenografted mice revealed anti-tumor potential of 
Rottlerin 
To evaluate in vivo efficacy of Rottlerin, we used a metastasis model based on intrasplenic 
injection of CRC cells into immune-deficient mice. The spleen being intensively blooded 
provides a way for  the transplanted cells to enter the blood circulation [237]. Thus, the 
intrasplenic model, represent partially the process of metastasis formation and excludes the 
processes of dissemination from the tumor tissue and invasion into the blood stream [238]. 
Metastasis formation begins with the local tumor enlargement from which cells invade the 
vascular and lymphatic system, circulate and finally extravasate into distant organs [239]. So 
far, no genetic mouse model of spontaneous tumors that arise in the intestines, become 
invasive, and metastasize to organs such as liver, lungs, and lymph nodes, as they do in 
humans is available. Thus xenografted models are often used to study the whole progression 
of the tumor to the metastatic stage. However, the orthotopic model also has several 
disadvantages, as it is time consuming, complex and only 50% of successful transplanted 
mice show metastasis to the lymph nodes and very rarely to the liver since majority of the 
animals die before liver metastasis occur due to tumor burden [238, 240, 241]. Another 
xenograft intrasplenic model includes implantation of malignant human CRC cells into the 
spleens of immune-deficient mice. The studies suggest that this model can produce liver 
metastasis originated from the tumors of the spleen [242]. This animal model is now a 
popular choice to study primary tumor growth and liver metastasis. Therefore, in this study, 
we used the intrasplenic mouse model employing endogenously MACC1 expressing 




HCT116 cells, to analyze the potential of Rottlerin in halting tumor progression and 
metastasis caused by MACC1. 
Further, tumor progression was monitored using non-invasive bioluminescence imaging to 
follow the process of MACC1-induced human CRC progression in vivo. Bioluminescence 
imaging is based on the detection of photons, which are excised as a side product in an 
enzymatic reaction. Bioluminescence imaging in animal models requires a reporter construct 
that leads to production of the luciferase enzyme. We used HCT116 cells stably expressing a 
plasmid for the firefly luciferase gene. Firefly luciferase originates from the North American 
firefly Photinus Pyralis and catalyzes the oxidation of luciferin under ATP consumption and 
emission of light. Monitoring of intrasplenically implanted HCT116 cells into NOD-SCID mice 
revealed an increased bioluminescence signal in the spleen region over time. 
Many non-invasive imaging modalities besides bioluminescence have been described for 
their use in small animals, such as X-ray computed tomography (CT), magnetic resonance 
imaging, single photon emission computed tomography (SPECT), positron emission 
tomography and fluorescence imaging [243]. However, bioluminescence bears several 
advantages compared to other modalities such as its ease of application, cost effectively and 
high-sensitivity. It is free from exposure to radiation and provides a relative measure of the 
signal to the amount of viable cells. Moreover, mammalian tissue has only a very low intrinsic 
bioluminescence, therefore generates an optimized signal-to-noise ratio [244]. The main 
limitation of bioluminescence is its anatomic resolution as it only provides 2D images that are 
relatively low resolution, which is a not very important demand for our study. So we preferred 
bioluminescence imaging for our study. 
The bioluminescence signal from the spleen formed by CRC cells appeared already on day 5 
as a weak signal in both solvent and Rottlerin treated mice. In the solvent treated control 
group, the spleen signal increased overtime until day 27 wherein, the primary tumor became 
very big and the experiment had to be terminated due to ethical reasons. Rottlerin treatment 
abrupted the tumor progression by retarding the growth of tumor cells in the spleen and thus 
reducing the primary tumor size in that organ. Additionally, the level of human MACC1 
expression from the mouse spleen bearing human CRC tumor cells was also reduced in the 
Rottlerin treated group as compared with the control group suggesting that decreased 
MACC1 levels in the primary tumors contribute to the retarded tumor growth. However, up to 
day 27, no liver metastasis was observed in solvent treated control group. This was a bit 
surprising since many comparable studies demonstrated metastasis formation from day 6-8 
using the same mouse model [245, 246]. Even the autopsy from the control mice showed 
clean livers with little or no metastasis. The major limitation with such kind of in vivo study is 




the determination of the optimal endpoint. The optimal endpoint should be neither too early, 
otherwise metastases might not be visible, nor too late to reduce the suffering of the animal 
and avoid tumor burden-caused death. But in this study, the end point came early and 
animals could not be kept longer to see metastasis in the liver because of large primary 
tumors in the spleen and had to be sacrificed due to ethical reasons. Hence, the anti-
metastatic effect of Rottlerin could not be addressed in this experiment. Nevertheless, the 
study definitely provides first evidence that Rottlerin inhibits MACC1 expression and impairs 
the tumor progression of CRC cells in vivo. Thus, we conclude that Rottlerin could be 
exploited as a potential small molecule inhibitor against CRC. 
5.3.3 Pros and cons of using small molecule inhibitors for targeting MACC1 
In 1800s, bacteriologist Paul Ehrlich coined a term “magic bullet” for chemicals with the 
ability to specifically target microorganisms. His concept has now emerged in many fields 
including cancer treatments for therapies other than conventional chemotherapeutic drugs. 
Such innovative cancer-treatment strategies include development of monoclonal antibodies 
(mAbs), small molecules, peptide mimetics and antisense oligonucleotides [247] with each 
class possessing their own share of selectivity, specificity, efficacy and applicability issues. 
Using anti-sense oligonucleotides (RNA interference), dose optimization is very complex. 
Moreover, the systemic application to organisms is challenged by the efficient delivery into 
the cell [248]. In contrast, both small molecule inhibitors were able to enter the cell without 
further additives. Systemic Rottlerin application inhibited the MACC1 expression in vivo 
providing the basic evidence for its applicability to treat CRCs. As compared to mAbs and 
peptide mimetics, small-molecule agents, owing to their small size, can translocate through 
plasma membranes, therefore be developed to target any molecules regardless of their 
cellular localization. In addition, therapeutic anti-sense oligonucleotides or mAbs require 
relatively complex processes with extremely high monetary costs compared with small-
molecule inhibitors. In contrast, small-molecule agents are less expensive and have better 
pharmacological properties [249].  
The major issue with small molecule inhibitors remains the specificity. Targeting MACC1 
promoter activity with the small molecules will not be solely restricted to the inhibition of 
MACC1 expression, but might have some off-target effects too. However, in solid cancers, 
oncogenesis is a multi-step, multi-factorial process and its pathogenesis is not because of a 
single target. In this context, a single targeted therapy seems theoretically an unfavourable 
strategy. Therefore, this lack of specificity with small molecules could be potentially 




favourable albeit with some risk of increased toxicity which should be assessed during 
clinical studies. 
5.3.4 Summary and Scope: Rottlerin and Lovastatin as potential drugs for treating 
CRCs 
MACC1 was found to be a prognostic biomarker for metastasis-free survival of the CRC 
patients independent of age, sex, tumor infiltration, nodal status, and lymph vessel invasion. 
The five-year survival of patients with low MACC1 expression in their primary tumor is 80% 
which drops to 15% among the patients with high MACC1 level. Therefore, it is now clear 
that MACC1 plays an important role in CRC progression and metastasis. MACC1 is involved 
in the crucial step of transition from the benign to the malignant phenotype in the Fearon and 
Vogelstein carcinoma sequence [135]. Thus, targeting MACC1 holds strong promise in 
abrupting adenoma to carcinoma progression. 
This is the first study identifying small molecule MACC1 inhibitors. Herein, we provide 
evidence that small molecule drugs, Rottlerin and Lovastatin, inhibit MACC1 expression and 
thereby MACC1-induced proliferation and cell motility in vitro. Both the drugs are 
transcriptional suppressors which inhibit the binding of c-Jun to the MACC1 promoter and 
reduce Sp1 levels, collectively leading to decrease MACC1 transcription. Further in vivo 
studies were carried out with Rottlerin alone, and in vivo data demonstrated a reduced 
growth of the primary tumor and inhibition of MACC1 expression in those tumor cells by 
Rottlerin treatment in xenografted mice. Based on these results, we suggest that Rottlerin 
might be of clinical relevance in the management of CRC patients. As MACC1 expression in 
tumors from CRC patients is an indicator for development of metastases [108], Rottlerin is 
not only able to restrict primary tumor formation but might also inhibit metastasis as well. This 
should be validated again in a mouse xenograft model that can undergo liver metastasis 
within an optimal end point time. 





Figure 5.5: MACC1 regulation and its transcriptional inhibition by Rottlerin and Lovastatin. 
Adapted from Arlt et al. [135] 
 
Moreover, studies performed by Stein and colleagues show, that the level of free circulating 
MACC1 transcripts in the plasma of CRC patients predict metastases and survival. Thus, 
patients at high risk of developing metastasis might be monitored based on their MACC1 
levels, which can be determined either via immunohistochemistry or qRT-PCR after tumor 
resection or via blood analysis. For patients with high MACC1 levels, Rottlerin treatment 
could be of particular value to restrict CRC progression and the development of 
metachronous metastases.  
Current treatment option of CRC patients includes surgical resection along with 
chemotherapy with drugs, such as 5-Fluoruracil, Leucovorin, Irinotecan or Oxaliplatin which 
mostly target the increased proliferation rate of cancer cells [250]. In the management of 
metastatic CRC, targeted therapies such as Cetuximab, Panitumumab or Bevacizumab in 
combination with above mentioned chemotherapy is used  following surgical resection [251]. 
However, for curing patients with primary CRC that is at high risk for recurrence and 
metastasis (stage III and high-risk stage II colon cancer), novel drugs targeting the metastatic 
potential of cells are required, since metastatic dissemination remains the major cause for 
the mortality associated with CRC. In this respect, Rottlerin presents substantial potential to 
be tested further into preclinical and clinical studies as neo-adjuvant or adjuvant therapy 
alone or in combination with standard chemotherapy to target tumor growth as well as to 







The present study identified the MACC1 promoter and elicited the role of the transcription 
factors AP-1, Sp1 and C/EBPs in regulating transcription of the MACC1 gene. Current 
investigations focussed mainly on AP-1 and Sp1 mediated regulation of MACC1 promoter. 
The possibility of other cis or trans acting transcription factors regulating MACC1 expression 
still remains and needs to be investigated in the future. To establish the role of GIPC1 as a 
transcription factor, its nuclear localization studies and further pinpointing the precise position 
on MACC1 promoter needs to be worked upon by designing more deletion constructs of the 
MACC1 promoter. In parallel, bioinformatics studies can aid in understanding the region 
responsible for its shuttling from cytoplasm to nucleus. 
The findings of the present study also revealed the potential of Rottlerin and Lovastatin as 
inhibitors of CRC progression by inhibiting MACC1 transcription. We are currently trying to 
establishing the role of Rottlerin in not just inhibiting the progression of CRC but also in the 
inhibition of metastasis associated with the MACC1 expression. Further studies addressing 
the long term drug tolerability and bioavailability of Rottlerin are required. We propose that in 
the clinical setting, CRC patients with high MACC1 levels in their primary tumors might be 
treated with Rottlerin as a targeted therapy to restrict MACC1 associated tumor progression 
as well as prevent MACC1 induced metastasis and cancer recurrence. Pre-clinical studies 
with Lovastatin on xenografted mice bearing human CRC cells endogenously expressing 
MACC1 are currently being performed. For Lovastatin, more preclinical data describing its 
safety profile is warranted. Moreover, studies including patient stratification on the basis of 
their previous medical history and genetic background may help in identifying cancer patients 
who will benefit from statin therapy.  
These investigations will further clarify the potential benefits of the clinical application of 
Rottlerin and Lovastatin on high risk CRC patients in their earlier stages to prevent the 
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